Country	Sample name	Latitude	Longitude

Poland	A	53° 50′02.83′′N	21° 03′30.36′′E

Poland	H	54° 23′21.42′′N	18° 28′42.18′′E

Germany	B	52° 13′09.87′′N	11° 42′25.14′′E

Germany	D	53° 25′51.60′′N	09° 46′39.78′′E

Denmark	I	56° 12′13.48′′N	08° 09′39.07′′E

Denmark	E	55° 56′16.98′′N	12° 28′35.70′′E

Sweden	F	58° 52′20.04′′N	14° 53′56.79′′E

Sweden	K	64° 36′27.31′′N	20° 57′04.32′′E

Ireland	G	53° 35′24.27′′N	08° 03′33.69′′W

UK	C	52° 29′17.12′′N	00° 55′59.12′′W

UK	J	52° 44′34.76′′N	01° 08′09.87′′W

Country	Sample name	Latitude	Longitude

Sweden	F	58° 52′20.04′′N	14° 53′56.79′′E

Sweden	K	64° 36′27.31′′N	20° 57′04.32′′E

Ireland	G	53° 35′24.27′′N	08° 03′33.69′′W

UK	C	52° 29′17.12′′N	00° 55′59.12′′W

UK	J	52° 44′34.76′′N	01° 08′09.87′′W


	ExpressHMM	ANTM

Probe sensitivity	65%	44%

Novel probes predicted	65%	49%

Overlap exon Sensitivity	58%	58%

Novel transfrags predicted	27%	58%

5' Splice site sensitivity	16%	9%

3' Splice site sensitivity	16%	13%

	ExpressHMM

Probe sensitivity	65%

Novel probes predicted	65%

Overlap exon Sensitivity	58%

Novel transfrags predicted	27%

5' Splice site sensitivity	16%

3' Splice site sensitivity	16%


Diagnosis	Parasite	Early [n (%)]	Peak [n (%)]	Late [n (%)]	Total [n (%)]	P value1

Microscopy	P. vivax	9 (1.7)	13 (2.3)	3 (0.5)	25 (1.5)	0.066

P. falciparum	0	0	0	0	–

Mixed infection	0	0	0	0	–


Tandem repeat Family	Repeat Length	GC Content (%)	Genome Coverage (%)a	Consensus Sequenceb	Distribution

pBuM189	189	29	0.039	GCAAAAGACTCCGTCAATTA GAAAACAAAAAATGTTATAGTTTTGAGGATTAACC GGCAAAAACCGTATTATTTGTTATAT GATTTCTGTATGGAATACCGTTTTAGAA GCGTCTTTTATCGTATTACTCAGATATATCT TAAGATTTAGCATAATCTAAGAACTTTT TGAAATATTCACATTTGTCCA	D. buzzatii cluster species D. mojavensis

DbuTR198	198	34	0.027	AAGGTAGAAAGGTAGTTGGTGAGATAAACCAGAAAAA GAGCTAAAAACGGCTAAAAACGGCTAGAAAATAGCCA GAAAGGTAGATTGAACATTAATGGGCAAATGG ATGGATAAATAAGACTGGTCATCATCCAA TGAACAGAATCATGATTAAGAGATAGAAATA TGATTAGAAAGTAGGATAGAAAGGTTAGAAAG	D. buzzatii

Tandem repeat Family	Repeat Length	GC Content (%)	Genome Coverage (%)a

pBuM189	189	29	0.039

DbuTR198	198	34	0.027

Consensus Sequenceb	Distribution

GCAAAAGACTCCGTCAATTA GAAAACAAAAAATGTTATAGTTTTGAGGATTAACC GGCAAAAACCGTATTATTTGTTATAT GATTTCTGTATGGAATACCGTTTTAGAA GCGTCTTTTATCGTATTACTCAGATATATCT TAAGATTTAGCATAATCTAAGAACTTTT TGAAATATTCACATTTGTCCA	D. buzzatii cluster species D. mojavensis

AAGGTAGAAAGGTAGTTGGTGAGATAAACCAGAAAAA GAGCTAAAAACGGCTAAAAACGGCTAGAAAATAGCCA GAAAGGTAGATTGAACATTAATGGGCAAATGG ATGGATAAATAAGACTGGTCATCATCCAA TGAACAGAATCATGATTAAGAGATAGAAATA TGATTAGAAAGTAGGATAGAAAGGTTAGAAAG	D. buzzatii


Policosanol (Chemical formula)	Percent

Docosan-1-ol (C22-OH)	1.52 ± 0.24

Tricosan-1-ol (C23-OH)	2.12 ± 0.39

Tetracosan-1-ol (C24-OH)	2.02 ± 0.50

Hexacosan-1-ol (C26 -OH)	2.50 ± 0.16

Heptacosan-1-ol (C27−OH)	1.90 ± 0.25

Octacosan-1-ol (C28-OH)	75.44 ± 2.41

Nonacosan-1-ol (C29-OH)	2.55 ± 0.62

Triacontan-1-ol (C30-OH)	8.61 ± 1.20

Dotriacontan-1-ol (C32-OH)	3.34 ± 0.56

Policosanol (Chemical formula)	Percent

Octacosan-1-ol (C28-OH)	75.44 ± 2.41

Nonacosan-1-ol (C29-OH)	2.55 ± 0.62

Triacontan-1-ol (C30-OH)	8.61 ± 1.20

Dotriacontan-1-ol (C32-OH)	3.34 ± 0.56


Experimental groups	Lipid parameters (mg/dL)


	Based on parent ATS report	Based on child ATS report

MVPA of trips during the times reported by the parent	U = 390.5, p = 0.02*	U = 596.5, p = 0.02*

ATS trips (n = 99) 2.46 min (2.83)	ATS trips (n = 128) 2.40 min (2.68)

Non-ATS trips (n = 13) 0.76 min (0.95)	Non-ATS trips (n = 15) 0.81 min (0.87)

Missing trips = 170 (60.3%)	Missing trips = 139 (49.3%)

MVPA of trips during the hour before the classes (7:56–8:55)	U = 665.5, p = 0.02*	U = 955.0, p = 0.01*

ATS trips (n = 104) 4.99 min (4.11)	ATS trips (n = 146) 4.99 min (3.91)

Non-ATS trips (n = 19) 2.55 min (1.69)	Non-ATS trips (n = 20) 2.59 min (1.60)

Missing trips = 159 (56.4%)	Missing trips = 116 (41.1%)

MVPA of trips during the times reported by the parent	ATS trips (n = 99) 2.46 min (2.83)	ATS trips (n = 128) 2.40 min (2.68)

Non-ATS trips (n = 13) 0.76 min (0.95)	Non-ATS trips (n = 15) 0.81 min (0.87)

Missing trips = 170 (60.3%)	Missing trips = 139 (49.3%)

MVPA of trips during the hour before the classes (7:56–8:55)	U = 665.5, p = 0.02*	U = 955.0, p = 0.01*

ATS trips (n = 104) 4.99 min (4.11)	ATS trips (n = 146) 4.99 min (3.91)

Non-ATS trips (n = 19) 2.55 min (1.69)	Non-ATS trips (n = 20) 2.59 min (1.60)

Missing trips = 159 (56.4%)	Missing trips = 116 (41.1%)


Case	Sex, Age (years)	Previous operations	Fusion length	ASF	Cause and further treatment

1	M, 62	Yes	2	Yes	Patient had persitant back pain postoperatively and paresthesia in the lower extremity. MRI showed an adjacent vertebral fracture leading to an elongation of the initial fusion of up to 4 segments and second explorative operation due to persistant paresthesia. No specific cause was identifed for this. Sensation returned to normal in the further course.

2	F, 67	No	6	Yes	Early adjacent failure was caused by an osteoporotic cut out of the upper uncemented pedicle screws. This led to an elongation of the fusion by two segements with cement-augmentation.

3	F, 74	No	5	Yes	After the inital dorsoventral fusion, an osteoporotic adjacent segment failure in the upper instrumented vertebra caused the need of a fusion extension of one more segment with pedicle screw cement augmention. Thereafter, the patient developed a wound dehiscence. This led to a further operation for wound debridement and closure.

4	M, 65	No	6	Yes	This adjacent segment failure included a pedicle fracture causing a transient paresis of the hip flexion requiring immediate screw removal and nerve exploration. There was no nerve root damage. The fusion was elongated by 2 levels. The muscle regained full function in the follow-ups.

5	F, 72	No	4	Yes	This patient had a screw misplacement as idenfied by the CT-scan. The screw was causing irritation of the nerve root and had a cut out through upper vertebral plate. This complex cause of adjacent segment failure and spinal nerve compression lead to an early revision and elongation by one segment.

6	M, 85	No	5	Yes	This patient showed during the primary operation a poor bone quality (osteoporosis) with the need to use cement augmentation of the upper instrumented vertebra. During the early mobilisation process, the patient suffered an adjacent vertebral fracture with progression needing a revision with elongation of 2 more segments with careful cement augmentation.

7	F, 67	No	6	Yes	Due to osteoporotic bone, the upper pedicle screws were cement augmented. However, the poor bone quality caused an osteoporotic fracture with nerve irritation needing a revision surgery with elongation of the fusion by 2 segments. Unfortunately thereafter, a wound healing defect caused a further superfical wound revision.

8	F, 83	No	3	Yes	Due to a collapse of the upper vertebral plate during the mobilisation process, a surgical revision with elongation of 1 segment with cement augmentation was necessary.

Case	Sex, Age (years)	Previous operations	Fusion length	ASF	Cause and further treatment

1	M, 62	Yes	2	Yes	Patient had persitant back pain postoperatively and paresthesia in the lower extremity. MRI showed an adjacent vertebral fracture leading to an elongation of the initial fusion of up to 4 segments and second explorative operation due to persistant paresthesia. No specific cause was identifed for this. Sensation returned to normal in the further course.

2	F, 67	No	6	Yes	Early adjacent failure was caused by an osteoporotic cut out of the upper uncemented pedicle screws. This led to an elongation of the fusion by two segements with cement-augmentation.

3	F, 74	No	5	Yes	After the inital dorsoventral fusion, an osteoporotic adjacent segment failure in the upper instrumented vertebra caused the need of a fusion extension of one more segment with pedicle screw cement augmention. Thereafter, the patient developed a wound dehiscence. This led to a further operation for wound debridement and closure.

4	M,	N	6	Y	This adjacent segment failure inc

	 65	o		es	luded a pedicle fracture causing a transient paresis of the hip flexion requiring immediate screw removal and nerve exploration. There was no nerve root damage. The fusion was elongated by 2 levels. The muscle regained full function in the follow-ups.

5	F, 72	No	4	Yes	This patient had a screw misplacement as idenfied by the CT-scan. The screw was causing irritation of the nerve root and had a cut out through upper vertebral plate. This complex cause of adjacent segment failure and spinal nerve compression lead to an early revision and elongation by one segment.

6	M, 85	No	5	Yes	This patient showed during the primary operation a poor bone quality (osteoporosis) with the need to use cement augmentation of the upper instrumented vertebra. During the early mobilisation process, the patient suffered an adjacent vertebral fracture with progression needing a revision with elongation of 2 more segments with careful cement augmentation.

7	F, 67	No	6	Yes	Due to osteoporotic bone, the upper pedicle screws were cement augmented. However, the poor bone quality caused an osteoporotic fracture with nerve irritation needing a revision surgery with elongation of the fusion by 2 segments. Unfortunately thereafter, a wound healing defect caused a further superfical wound revision.

8	F, 83	No	3	Yes	Due to a collapse of the upper vertebral plate during the mobilisation process, a surgical revision with elongation of 1 segment with cement augmentation was necessary.


		Leisure-time physical activity	p

	Total N (%)	Yes (%)	No (%)

Feel too tired	62 (63.3)	59.3	64.8	0.612


Active ingredient	Abbreviation/Pharmaceutical preparation	Trade name (US)	Manufacturer	Approval status (US)	Notes

Methylphenidate hydrochloride	MPH-MR08 (modified-release preparation)	RitalinR LA (using SODAS delivery system developed by Elan)	Novartis	available in US and Switzerland

Methylphenidate hydrochloride	MPH-TDS Patch for transdermal drug delivery (o.a.d); 12 h duration of action	DaytranaR DOT matrix transdermal technology	Shire (in license from Noven)	US approval (children age 6–12 years) April 2006; 2nd line to oral drugs	Skin sensitization reported in 13–22% of subjects wearing the patch; product had been deemed non-approvable by FDA before (April 2003)

Dexmethylphenidate, a non-racemic form of methylphenidate:	d-MPH (the active isomer of methylphenidate)	FocalinR	Novartis (in license from Celgene)	Approved in US

Dexmethylphenidate, a non-racemic form of methylphenidate:	d-MPH-ER (extended release formulation)	FocalinR XR	Novartis (in license from Celgene)	US approval (for "children, adolescents, and adults") May 2005

Lisdexamphetamine dimesylate	LisDEX; (pharmaceutical preparation with a o.a.d. dosing schedule)	NRP104	Shire (in license from New River Pharmaceuticals)	US approval (for children age 6–12 years) granted in 2007	Reduced abuse potential expected because amphetamine is linked to L-lysine and does no become active until metabolized in the gastrointestinal tract

Mixed amphetamine salts	MAS (immediate and extended release formulations	AdderallR, AdderallR XR	Shire	Available in US	Unlikely to be approved in Europe

ModafinilSuccessor compound: Armodafinil	MOD; dopamine reuptake inhibitor; effects on neuropetides possibleARM	SparlonR (licensed in US and UK as ProvigilR for narcolepsy)NuvigilR	Cephalon(SparlonR was planned to be co-promoted in the US by McNeil, a sister company of Janssen-Cilag)	After receiving a non-approvable letter for modafinil in ADHD from the FDA in August 2006, Cephalon refocused its R&D on armodafinil [61]	Suspected serious adverse events (skin rash/Stevens-Johnson syndrome) in association with modafinil


Current UK Vaccination Against Invasive Meningococcal Disease

Vaccine (Serogroups)	Year Introduced into schedule	Age given

B	2015	8 weeks, 16 weeks, 1 year

C	1999	1 yeara

ACWY	2015	14 years, University students 19–25 years

Current UK Vaccination Against Invasive Meningococcal Disease

Vaccine (Serogroups)	Year Introduced into schedule

B	2015

C	1999

ACWY	2015

Current UK Vaccination Against Invasive Meningococcal Disease

Age given

8 weeks, 16 weeks, 1 year

1 yeara

14 years, University students 19–25 years


Cell type	AR expression (method)	Reference

Stem cells and progenitor cells

Hematopoietic stem cell	Yes (RT-PCR, IF)	(33, 34)

Common myeloid progenitor	Yes (RT-PCR)	(33)

Common lymphoid progenitor	Yes (RT-PCR)	(33)

Granulocyte-macrophage progenitor	ND

Common dendritic cell (DC) progenitor	ND

Megakaryocyte-erythroid progenitor	ND

Erythroblast	Yes (binding assay)	(32)

Early T cell progenitor	ND

Myeloid-derived cells

Megakaryocyte	Yes (IHC, RT-PCR, IF)	(37, 38)

Platelet	Yes (IF)	(38)

Erythroid cell (nucleated and enucleated)	Not expressed (IHC)	(37)

Monocyte	Yes (RT-PCR)	(37)

Macrophage	Yes (C+NC) (flow, IF, IHC, RT-PCR)	(16, 36, 37, 39)

Myeloid-derived DC	Not expressed (WB)	(40)

Myelocyte	Yes (IHC)	(37)

Metamyelocyte	Yes (IHC)	(37)

Neutrophil (band cell)	Yes (IHC)	(37)

Neutrophil (segmented)	Yes (IHC)	(37)

Mature eosinophil	Not expressed (IHC)	(37)

Basophil	ND

Mature mast cell	Yes (ImmGold)	(35, 41)

Lymphoid-derived cells

DN T cell	Yes (binding assay)	(42)

DP T cell	Yes (binding assay)	(42)

CD4+ T cell	Yes (C+NC) (flow, IF, binding assay)	(17, 28, 42)

CD8+ T cell	Yes (C+NC) (binding assay)	(17, 42)

Plasmacytoid DC	ND

Pro-B cell	Yes (WB)	(43)

Pre-B cell	Yes (WB)	(43)

Immature B cell	ND

Mature B cell	Not expressed (IHC, WB)	(37, 43)

Other

Thymic epithelial cells	Yes (IF)	(44)

Bone marrow stromal cells	Yes (IHC, WB)	(37, 43)


Query	Parameters inquired	Fluorescent wavelengths

1	FS, SS	2, 3 or 4

2	FS, SS, CD5	2, 3 or 4

3	FS, SS, CD5, CD20	2, 3 or 4

4	FS, SS, CD5, CD20, CD19, CD34	4


	LOS (days)	Av. daily weight gain (gr)

	β	95% C.I.	Pr(>|t|)	β	95% C.I.	Pr(>|t|)


AKI progression	Number of patients	ICU mortality	p

AKI I (n = 4259)

with rising creatinine values	1995 (46.8%)	522 (26.2%)	< 0.0001

with falling creatinine values	2264 (53.2%)	334 (14.8%)

AKI II (n = 857)

with rising creatinine values	439 (51.2%)	157 (35.8%)	< 0.0001

with falling creatinine values	418 (48.8%)	65 (15.6%)

AKI III (n = 2782)

with rising creatinine values	639 (23%)	318 (49.8%)	< 0.0001

with falling creatinine values	296 (10.6%)	62 (20.9%)

AKI III based on RRT criteria	1847 (66.4%)	999 (54.1%)

AKI I/AKI II progressing to AKI III	1664 (59.8%)	796 (47.8%)	p = 0.029

AKI III without prior AKI I/AKI II	1118 (40.2%)	583 (46.2%)


Yes (+)	LBP+	LBP+	LBP−	LBP−	Missing answers on pain 	LBP	SP 	LBP 	SP

No (−)	SP+	SP−	SP+	SP−	PIW+	PIW+	PINT+	PINT+

Number of workers n (%)	238 (45)	101 (19) 	47 (9)	79 (15)	60 (12)	156 (30)	96 (18)	180 (34)	147 (28)


	Profile Width	Neff

Superfamily	Full	Trimmed	Full	Trimmed

(Trans)glycosidases	410.4	23.93	13.11	3.21

4-helical cytokines	85.71	43.57	4.3	2.86

alpha/beta-Hydrolases	509.43	22.32	16.32	3.65

Cytochrome c	413.62	18.86	12.64	3.7

E Set domains	182.73	33.27	7.99	3.16

FAD/NAD(P)-bindin	616.		15


Zones	Most Used Pesticides (Top 5) in %	Cumulative %

1	2	3	4	5

Obala	Ridomil (8%)	Onex (6.3%)	Actara (5.7%)	Callomil (5%)	Lamida Gold, Parastar and Plantomil (4.7% each)	39.4

Foumbot	Gramoxone (12.6%)	Timide (7.4%)	K-optimal (7.1%)	Roundup (6.7%)	Cigogne and Pencozeb (4.1% each)	42

Santa	Gramoxone (12.7%)	Banko (12%)	Pencozeb (8%)	Roundup and Mancozan (6.7% each)	Parastar (4.7%)	50.8

Njombe–Penja	Gramoxone (12.8%)	Pyriforce (9.4%)	Glyphader (7.2%)	Ridomil and Supraxone (4.7% each)	Roundup and Capsidor (4.3% each)	47.4

Ngong–Garoua	Roundup (23.7%)	Atrazine (20.1%)	Gramoxone (15.9%)	Diuron (14.8%)	Biosec Roundup 720 (3.2%)	80.9

Zones	Most Used Pesticides (Top 5) in %	Cumulative %

1	2	3	4	5

Santa	Gramoxone (12.7%)	Banko (12%)	Pencozeb (8%)	Roundup and Mancozan (6.7% each)	Parastar (4.7%)	50.8

Njombe–Penja	Gramoxone (12.8%)	Pyriforce (9.4%)	Glyphader (7.2%)	Ridomil and Supraxone (4.7% each)	Roundup and Capsidor (4.3% each)	47.4

Ngong–Garoua	Roundup (23.7%)	Atrazine (20.1%)	Gramoxone (15.9%)	Diuron (14.8%)	Biosec Roundup 720 (3.2%)	80.9


F0	F1	F2	F3

Hip center speed (m/s)	Shoulder center speed (m/s)	Right hip speed (θ/s) Frontal plane	Right hip angle (θ) Frontal plane


Variables	GLM resultsinteraction effecta	Statistical changes over time(p value)	Adjusted mean differences between groups over timeb(Clinical changes)

	Group * Time	T1 → T2	T1 → T2

EORTCQLQ-C30:

Global quality of life	12.5	.000	+8.2

Functional scales:

Physical	118.5	.000	- 16.2

Role	30.1	.000	- 11.0

Emotional	9.8	.002	+8.5

Cognitive	7.9	.005	- 6.0

Social	8.4	.004	- 7.0

Symptom scales:

Fatigue	22.7	.000	+12.0

Nausea/vomiting	4.7	.030	+3.4

Pain	13.3	.000	+8.6

Dyspnea	0.6	.419	+1.7

Insomnia	1.7	.184	+4.0

Appetite loss	0.1	.707	- 1.0

Constipation	8.6	.004	+7.5

Diarrhea	0.4	.545	- 1.1

Financial difficulties	51.7	.000	+21.7

Sense of Coherence	17.3	.000	- 6.5

Spiritual Perspective Scale	31.0	.000	- 6.6

Religious Coping (+)	9.8	.002	- 6.5

Religious Coping (−)	3.5	.060	+4.3


Days in EB formation	Post EB differentiation	Differentiation conditions	Chondrogenic markers studied	Cells line(s)	Reference

5	Encapsulation of EBs in PEG hydrogel for 17 days	The EBs in hydrogel were differentiated in presence of chondrogenic medium (CM) treated with BMP-2 and TGF-β1	Type I, II, X collagen, and osteocalcin. Proteoglycans content measurement	Mouse-D3 and human-BG03	[12–15]

N/R	EB cells were seeded on ceramic particles	Cells on the ceramic scaffold was differentiated in vitro for 21 days in CM supplemented with TGF-β3 and 21 days of in vivo maturation	Morphology was studied and proteoglycans content was analyzed	Mouse-IB10, human MSC, and Goat MSCs	[4]

7 RA from day 2	EBs were plated	RA-treated EB outgrowth culture was treated with TGF-β3	D15: proteoglycans, Col2a1, Sox9, Col10a1 and MMP13	Mouse-CGR8, E14Tg2a, EFC1	[16]

28	After 4 weeks the EBs were dissociated and self-assembled for additional 4 weeks	EBs were differentiated in chondrogenic medium supplemented with combinations of TGF-β1, TGF-β3, BMP-2, and IGF-1 (100 ng/mL)	Sox9, Col1a1, Col2a1	Human-BG01V	[17]

Days in EB formation	Post EB differentiation	Differentiation conditions	Chondrogenic markers studied	Cells line(s)	Reference

N/R	EB cells were seeded on ceramic particles	Cells on the ceramic scaffold was differentiated in vitro for 21 days in CM supplemented with TGF-β3 and 21 days of in vivo maturation	Morphology was studied and proteoglycans content was analyzed	Mouse-IB10, human MSC, and Goat MSCs	[4]

7 RA from day 2	EBs were plated	RA-treated EB outgrowth culture was treated with TGF-β3	D15: proteoglycans, Col2a1, Sox9, Col10a1 and MMP13	Mouse-CGR8, E14Tg2a, EFC1	[16]

28	After 4 weeks the EBs were dissociated and self-assembled for additional 4 weeks	EBs were differentiated in chondrogenic medium supplemented with combinations of TGF-β1, TGF-β3, BMP-2, and IGF-1 (100 ng/mL)	Sox9, Col1a1, Col2a1	Human-BG01V	[17]


	Anteparturm hemorrhage	Transverse lie	Placenta previa	Breech presentation	Ectopic pregnancy	Twins	Poly /oligo hydromnious

Very confident	23.3	13.3	10	13.3	3.3	13.3	0

Confident	50	60	23.3	56.7	16.7	60	33.3

Not confident	10	13.3	46.7	23.3	40	27.3	43.3

Cannot measure/diagnose	16.7	13.3	20	6.7	40	0	23.3

	Anteparturm hemorrhage	Transverse lie	Placenta previa	Breech presentation	Ectopic pregnancy	Twins	Poly /oligo hydromnious

Very confident	23.3	13.3	10	13.3	3.3	13.3	0

Confi	5	6	23	56	16.

	Anteparturm hemorrhage	Transverse lie	Placenta previa	Breech presentation	Ectopic pregnancy	Twins	Poly /oligo hydromnious

dent	0	0	.3	.7	7	60	33.3

Not confident	10	13.3	46.7	23.3	40	27.3	43.3

Cannot measure/diagnose	16.7	13.3	20	6.7	40	0	23.3


Bacterial strain	Source	Reference

L. sakei 23K	Sausage	[66,67]

L. sakei MF1053	Fermented fish (Norwegian "Rakfisk")	[30]

L. sakei LS 25	Commercial starter culture for salami sausage	[68]

L. sakei Lb790x	Meat	[69]

L. sakei LTH673	Fermented sausage	[70,71]

L. sakei MF1328	Fermented sausage	[30]

L. sakei MF1058 (TH1)	Vakuum-packed cooked meat, protective culture	[9,10]

L. sakei CCUG 31331a (DSM 15831b, R 14 b/a)	Fermented sausage, type strain for L. sakei subsp. carnosus	[27,72]

L. sakei DSM 20017b (ATCC 15521c)	Sake, alcoholic beverage made by fermenting rice, type strain for L. sakei subsp. Sakei	[27]

L. sakei Lb16 (Lb1048d, CCUG 42687a)	Minced meat	[31,73]


	Sex

T	M	F

N	Mean difference ± SD(mm)	P	N	Mean ± SD	P	N	Mean ± SD	P


Ligands	XPGScore	Winning score	CDM

2XYT-based α7 nAChR-LBD	3SQ6-based α7 nAChR-LBD

Acetylcholine	−4.68	−4.812	−4.812	0.132

epibatidine	−5.2	−8.725	−8.725	1.000

nicotine	−3.1	−7.512	−7.512	0.731

cytisine	−3.65	−6.362	−6.362	0.476

PNU282987	−4.518	−5.878	−5.878	0.368

mecamylamine	−3.564	−4.873	−4.873	0.145

MG624	−4.954	failed to dock	−4.954	0.163

methyllycaconitine	−5.829	failed to dock	−5.829	0.357

Hexamethonium	−2.786	−1.001	−2.786	−0.318


Predictors	B

Preference	0.21

Originality	0.58

Ambiguity	0.32

Understanding	− 0.39


Methylated bases in 100 bp	SCREAM2	FAMAa	FAMAb	SPCHa	SPCHb

ntropy (Hχ)		.08	7	0.015

χ2 treatment	ns	<0.001	<0.001	ns	<0.001

χ2 inheritance	ns	ns	ns	ns	<0.001


ESTs per unigene	H. erato	H. melpomene

1 (singletons)	319	256

2	13	31


Gene 	Sequence	bp

Beclin-1	Sense 5′ CCAGATGCGTTATGCCCAGAC 3′ Anti-sense 5′ CATTCCATTCCACGGGAACAC 3′	149

mTOR	Sense 5′ AAACTGCACGTCAGCACCATC 3′ Anti-sense 5′ AGCCGTCTCAGCCATTCCA 3′	192

ATG5	Sense 5′CCATCAATCGGAAACTCATGGA 3′ Anti-sense 5′ATCTGCAGCCACAGGACGAA 3′	128

ATG7	Sense 5′ CTGTAACTTAGCCCAGTACCCTGGA 3′ Anti-sense 5′TACGGTCACGGAAGCAAACAAC 3′	113

Actin	Sense 5′TGGCACCCAGCACAATGAA 3′ Anti-sense 5′CTAAGTCATAGTCCGCCTAGAAGCA 3′	128


	Educationa	Household income (LICO)b	Neihgbourhood SEPc	Combined SEPd

A- Maternal and infant health status indicators

1. Preterm Birth	+	NS	NS	+ (*) (low-high)

2. Small for gestational Age	NS	+	+	+ (low-low)

3. Self rated health	+	+	+	+ (low-low)

4. Postpartum Depression	+	+	+	+ (low-low)

5. Pre-pregnancy BMI (<18.5)	+	+	+	+ (low-low)

6. Pre-pregnancy BMI (>24.5)	+	+	NS	+ (low-high)

B- Prenatal care

7. First prenatal care visit	+	+	+	+ (low-low)

8. Timing of ultrasound	-	NS	NS	NS

9. HIV testing (no)	NS	-	NS	+ (low-low)

10. Received enough information during pregnancy	+	+	+	+ (low-low)

11. Weight gained during pregnancy (kg) - (Below recommended range)	+	+ (*)	NS	+ (*) (low-high)

12. Weight gained during pregnancy (kg)-more (Above recommended range)	+	+	NS	+ (low-high)

C- Labor and deliveryexpereinces

13. Type of birth (caesarean)	NS	-	NS	+ (low-high)

14. Epidural for a vaginal birth	-	-	NS	+ (low-high)

15. Shaving for a vaginal birth	+	+	+	+ (low-high)

16. Position for vaginal birth (not laying flat)	NS	+	+	+ (low-low)

D- Medical care during the neonatal period

17. Infant hospital readmission	NS	NS	NS	NS

18. Infant needing non-routine neonatal care after discharge?	-	-	-	- (low-low)

19. Baby admitted to NICU after birth	NS	NS	NS	NS

20. Length of hospital stay after caesarean birth (More than average)	NS	NS	+	+ (high-low)

21. Length of hospital stay after vaginal birth (More than average)	+ (*)	NS	NS	NS

E- Postpartum infant care & maternal reflections on the overall experience of health care

22. Any breastfeeding at 3 months	+	+	-	+ (low-high)

23. Any breastfeeding at 6 months	+	+	-	+ (low-high)

24. Overall experience of labor and birth	NS	+	NS	+ (low-high)

25. Satisfaction with previous aspects of maternity care	+	+(*)	NS	NS

	Educationa	Household income (LICO)b	Neihgbourhood SEPc	Combined SEPd

16. Position for vaginal birth (not laying flat)	NS	+	+	+ (low-low)

D- Medical care during the neonatal period

17. Infant hospital readmission	NS	NS	NS	NS

18. Infant needing non-routine neonatal care after discharge?	-	-	-	- (low-low)

19. Baby admitted to NICU after birth	NS	NS	NS	NS

20. Length of hospital stay after caesarean birth (More than average)	NS	NS	+	+ (high-low)

21. Length of hospital stay after vaginal birth (More than average)	+ (*)	NS	NS	NS

E- Postpartum infant care & maternal reflections on the overall experience of health care

22. Any breastfeeding at 3 months	+	+	-	+ (low-high)

23. Any breastfeeding at 6 months	+	+	-	+ (low-high)

24. Overall experience of labor and birth	NS	+	NS	+ (low-high)

25. Satisfaction with previous aspects of maternity care	+	+(*)	NS	NS


Demographic Variables	Number

Ages

15-19	2

20-24	2

25-29	2

30-34	1

35-39	2

40-44	1

45-49	0

Total	10

Educational Attainment

None	1

Grades 1-4	1

Grades 5-8	3

Grades 9-12	5

Tertiary education	0

Total	10

Age at first birth

15-19	6

20-24	3

25-29	1

30-34	0

35-39	0

40-44	0

45-49	0

Total	10

Marital Status

Single	8

Customary marriage	0

Civil Marriage	0

Cohabiting	2

Total	10

Number of live births

0-2	2

04-Mar	6

5+	2

Total	10

Employment Status

Unemployed	7

Employed	2

Other: e.g. self-employed as petty trader	1

Total	10

Demographic Variables	Number

04-Mar	6

5+	2

Total	10

Employment Status

Unemployed	7

Employed	2

Other: e.g. self-employed as petty trader	1

Total	10


Ingredient	Fish oil-based diet1	Saturated fat-based diet2

	g (%)	Kcal	g (%)	Kcal (%)

Protein	23.7	20	23.7	20

Carbohydrate	41.4	35	41.4	35

Fat1	23.6	45	23.6	45


Agent*	Time (s)	Capping efficiency

Acetic anhydride	15	60 ± 4%

Acetic anhydride	30	81 ± 2%

Acetic anhydride	60	92 ± 2%

Acetic anhydride	120	95 ± 2%

DMT-dT	15	91 ± 2%

DMT-dT	30	94 ± 1%

DMT-dT	60	97 ± 1%


		Abnormalcardiometabolic profile	Normalcardiometabolic profile	TOTAL

Untreated	"Normal" weight(BMI = 18.5 - 24.9)	23.5%(16.3 million people)b	76.5%(53.0 million people)	100%(69.3 million people)

Treated	"Overweight"(BMI = 25.0 - 29.9)	48.7%(34.1 million people)	51.3%(35.9 million people)c	100%(70.0 million people)

	"Obese"(BMI ≥ 30.0)	68.3%(42.0 million people)	31.7%(19.5 million people)c	100%(61.5 million people)

TOTAL	46%92.4 million people	54%108.4 million people	100%200.8 million people


	Number of controls

	10	60	110	160	210

Percentage of results that included the mutation (%)	100	100	100	100	100

Percentage of mutation loci in the top hit (%)	46	43	37	38	37

Mean length of haplotypes (number of SNPs)	629	546	441	410	383

	Number of controls

	10	60	110	160	210

Percentage of results that included the mutation (	10			100	10

	Number of controls

	10	60	110	160	210

%)	0	100	100		0

Percentage of mutation loci in the top hit (%)	46	43	37	38	37

Mean length of haplotypes (number of SNPs)	629	546	441	410	383


Cantilever ID	L μm	-Sphere -material	Sphere number	Sphere diameter, μm	Resonance Frequency -kHz	ΔLm μm

DNP 6A	108	Gold	–	0	62.8	–

		19300	1	3.8	56.0	+1.9

		kg·m−3	2	5.7	46.8	−1.4

			3	9.5	31.2	−1.1

			–	0	62.8	–

Cantilever ID	L μm	-Sphere -material	Sphere number	Sphere diameter, μm	Resonance Frequency -kHz	ΔLm μm

			3	9.5	31.2	−1.1

			–	0	62.8	–


Variable

Demographic characteristics

Mean age (in years) [Mean(SD)]

Female [n(%)]

Retired [n(%)]

Concomitant medications [n(%)]

Anxiolytics

Anticholinergics

Antidepressants

Sedative-hypnotics

Mood stabilizers

Mental comorbidities [n(%)]

Sleep disorder

Depression

Anxiety disorder

Other psychotic disorder#

Resource utilization and cost (prior 3 months)

Mean number of hospitalizations

Mean number of outpatient visits

Direct medical cost ($) [Mean(SD)]


All Sounds > Baseline

Region	Number of Voxels

Right Frontal Cortex	14335

Frontal pole

Frontal orbital cortex

Middle frontal gyrus

Pars opercularis

Pars triangularis

Right Temporal Cortex	2243

Middle temporal gyrus, posterior division and temporoccipital part

Superior temporal gyrus, posterior division

Heschl’s gyrus

Left Temporal Cortex	874

Middle temporal gyrus, posterior division

Superior temporal gyrus, posterior division

Heschl’s gyrus

Left Frontal Pole	48


	General evidence	Managerial Accounting tools	HRM tools	ICT tools	Outcomes	Open issues

Progressive patient care model	In some contexts implementation by law (e.g. Tuscany)Great autonomy of organizations on how to implement modelForms of implementation:poles; separation elective/unscheduled/emergency patients; distinct inpatient/outpatient pathways; emphasis on ED; pool beds; centralization of functions	Integrated Planning, Budgeting and Control systems (e.g. BSC)In concrete, however, MA tools not aligned to model (e.g. budgets still assigned to clinical wards)	New professional roles and a general reassignment of responsibilities (nurses and physicians)Need for:Competency based model;Separate professional/managerial career paths;Multi-source and 360° feedback system	Integrated electronic health records, to be jointly used and updated by physicians and nurses	Improved efficiency indicatorsIncreased patient satisfaction (medical and/or nursing tutor)More coordination between medical and surgical staffBetter implementation of clinical pathwaysLack of evidence in terms of improved clinical outcomes	Effective allocation of nurses to different settingsCorrect triage activity in ED and efficient allocations of patientsDesirability of medical day- or week- hospitalsInvolving professionals and of overcoming cultural barriersDefinition of clear repartition of responsibilities among professionals

Patient centered approach	The most analyzed aspect of PC is related to continuity of care among different settings (poorly explored within hospitals)An exception: analysis of general process improvements within EDs		New professional roles in hospitals (e.g. liason nurse)	ICT tools should ideally:prioritize information and detect individuals’ contextual situations,promote stronger inter-professional relationships with adequate exchange of information,enable interoperability and scalability between and within institutions,function across different platforms.Few pioneer experiences (e.g. Shared care platform)ICT tools still rudimental if compared to their potential	Significant relationships between specific elements of PC and outcomes, or between PC approach in general and a reduced ED utilization.Liason activities are associated with slightly higher (not significant), quality care transitions.Greater patient satisfactionImproved communication among professionalsGeneral evidence about the effects of PCC on clinical outcomes very limited	Poor attention of literature to PC within hospitalsNecessary switch from hospital information systems to health care information systemsNon exhaustive informationIndividuals involved are not tracedLack of tools to clearly assess PC

Lean approach	Application of various features of lean such as new employee roles, staffing and scheduling, communication and coordination, workspace layout, process design etc.Application of lean tools within settings (EDs, ORs, outpatient settings)Only few examples of lean applied to pathways		Staff empowerment and “bottom-up approach”, by allowing the frontline staff to identify problems and come up with appropriate solutions		Many examples of improvement in efficiency indicatorsFewer examples of improvement in clinical outcomesA number of studies find inconsistent the evidence about lean’s contribution to higher organizational performance	Lean is often felt to be “a constellation of disjointed and poorly connected activities”Lack of “system-wide” improvement philosophyThe “bottom-up approach” is not fully implemented in concrete and barriers to implementation persistNeed of more formation for inter-professional collaboration


Unigene No.	Gene name	Copies	%*

Fetal pituitary

Hs.1905	prolactin+#	312	9.46

Hs.119689	glycoprotein hormones, alpha +#	146	4.43

Hs.115352	growth hormone 1+#	48	1.46

Hs.274460	olfactory receptor 5V1#	48	1.46

Hs.195453	ribosomal protein S27+#	24	0.73

Hs.75415	beta-2-microglobulin+#	22	0.67

Hs.70312	cytochrome c oxidase 7A2+#	15	0.46

Hs.315164	hypothetical protein#	14	0.42

Hs.83484	sex determining region Y-box 4#	8	0.24

Hs.7917	DKFZP564K247 protein#	7	0.21

Hs.273385	guanine nucleotide binding protein alpha+#	7	0.21

Hs.165590	ribosomal protein S13#	7	0.21

Hs.131814	tankyrase#	7	0.21

Hs.173912	eukaryotic translation initiation factor+	6	0.18

Hs.119222	suppression of tumorigenicity 13+#	6	0.18

Hs.177530	ATP synthase+	5	0.15

Hs.177656	calmodulin 1+	5	0.15

Hs.241429	cDNA DKFZp586C1923#	5	0.12

Hs.330994	RAB9#	4	0.12

Hs.46328	fucosyltransferase 2#	4	0.12

Adult pituitary

Hs.115352	growth hormone 1+#	358	6.09

Hs.1905	prolactin+#	288	4.9

Hs.1897	proopiomelanocortin#	46	0.78

Hs.181165	eukaryotic translation elongation factor1#	45	0.77

Hs.273385	guanine nucleotide binding protein AS1+#	44	0.75

Hs.65149	growth hormone 2#	42	0.71

Hs.279789	glucose phosphate isomerase#	41	0.7

Hs.119689	glycoprotein hormones, alpha+#	37	0.63

Hs.77385	myosin, light polypeptide 6+#	30	0.51

Hs.278959	galanin-related peptide LOC51083#	25	0.43

Hs.247474	hypothetical protein FLJ21032#	21	0.36

Hs.180450	ribosomal protein S24#	20	0.34

Hs.155482	hydroxyacyl glutathione hydrolase#	19	0.32

Hs.76053	DEAD/H box polypeptide 5#	19	0.32

Hs.75360	carboxypeptidase E+#	18	0.31

Hs.112844	maternally expressed 3#	16	0.27

Hs.117950	phosphoribosylaminoimidazole carboxylase#	16	0.27

Hs.119598	ribosomal protein L3#	16	0.27

Hs.5464	skeletal muscle abundant protein#	16	0.27

Hs.179526	thioredoxin interacting protein #	15	0.26

Unigene No.	Gene name	Copies	%*

Hs.112844	maternally expressed 3#	16	0.27

Hs.117950	phosphoribosylaminoimidazole carboxylase#	16	0.27

Hs.119598	ribosomal protein L3#	16	0.27

Hs.5464	skeletal muscle abundant protein#	16	0.27

Hs.179526	thioredoxin interacting protein #	15	0.26


Variable	PFNA (n = 72)	DHS (n = 70)	P value

Total complications	15	31	0.003

 Patients affected	15 (20.8%)	31 (42.9%)	0.003

Medical complications	3	5	0.442

 Patients affected	3 (4.2%)	5 (7.1%)	0.442

Urinary tract infection	1	1	1.000

Pulmonary embolism	0	2	0.241

Atrial fibrillation	2	0	0.497

Acute renal failure	0	2	0.241

Orthopaedic complications	12	26	0.011

 Patients affected	12 (16.7%)	26 (37.1%)	0.011

Periprosthetic fracture	3 (4.2%)	11 (15.7%)	0.021

Prosthetic instability	1	2	0.617

Dislocation	1	3	0.363

Limb length discrepancy (>2.5 cm)	1	2	0.617

Abductor tendon deficiency	2	2	1.000

Heterotopic ossification	1	1	1.000

Intraoperative nerve injury	1	1	1.000

Aseptic loosening	0	1	0.241

Periprosthetic infection	2	2	1.000

Variable	PFNA (n = 72)	DHS (n = 70)	P value

Periprosthetic fracture	3 (4.2%)	11 (15.7%)	0.021

Prosthetic instability	1	2	0.617

Dislocation	1	3	0.363

Limb length discrepancy (>2.5 cm)	1	2	0.617

Abductor tendon deficiency	2	2	1.000

Heterotopic ossification	1	1	1.000

Intraoperative nerve injury	1	1	1.000

Aseptic loosening	0	1	0.241

Periprosthetic infection	2	2	1.000


WHO AFRO SLIPTA Checklist Audit Score Sheet (Section)	Total Points

Section 1: Documents & Records	25

Section 2: Management Reviews	17

Section 3: Organization & Personnel	20

Section 4: Client Management & Customer Service	8

Section 5: Equipment	30

Section 6: Internal Audit	10

Section 7: Purchasing and Inventory	30

Section 8: Process Control and Internal & External Quality Audit	33

Section 9: Information Management	18

Section 10: Corrective Action	12

Section 11: Occurrence/Incident Management & Process Improvement	12

Section 12: Facilities and Safety	43

Total Score	258

WHO AFRO SLIPTA Checklist Audit Score Sheet (Section)	Total Points

Section 1: Documents & Records	25

Section 2: Management Reviews	17

Section 3: Organization & Personnel	20

Sect	8

ion 4: Client Management & Customer Service

Section 5: Equipment	30

Section 6: Internal Audit	10

Section 7: Purchasing and Inventory	30

Section 8: Process Control and Internal & External Quality Audit	33

Section 9: Information Management	18

Section 10: Corrective Action	12

Section 11: Occurrence/Incident Management & Process Improvement	12

Section 12: Facilities and Safety	43

Total Score	258


Correlate	OR	95 % CI	p-value

Socio-demographic factors

Age


	Left hemisphere	Right hemisphere

V1

Smooth objects	0.92 ± 0.09	0.82 ± 0.09

Textured objects	1.63 ± 0.11	1.50 ± 0.13

V2

Smooth objects	0.92 ± 0.06	0.88 ± 0.06

Textured objects	1.33 ± 0.07	1.28 ± 0.09

V3

Smooth objects	0.98 ± 0.09	0.92 ± 0.06

Textured objects	1.26 ± 0.11	1.18 ± 0.09

LOC

Smooth objects	0.99 ± 0.09	1.00 ± 0.08

Textured objects	0.81 ± 0.09	0.82 ± 0.06

FFA

Smooth objects	0.96 ± 0.17	1.10 ± 0.10

Textured objects	0.79 ± 0.19	1.05 ± 0.15

	Left hemisphere	Right hemisphere

Textured objects	1.63 ± 0.11	1.50 ± 0.13

V2

Smooth objects	0.92 ± 0.06	0.88 ± 0.06

Textured objects	1.33 ± 0.07	1.28 ± 0.09

V3

Smooth objects	0.98 ± 0.09	0.92 ± 0.06

Textured objects	1.26 ± 0.11	1.18 ± 0.09

LOC

Smooth objects	0.99 ± 0.09	1.00 ± 0.08

Textured objects	0.81 ± 0.09	0.82 ± 0.06

FFA

Smooth objects	0.96 ± 0.17	1.10 ± 0.10

Textured objects	0.79 ± 0.19	1.05 ± 0.15


Study	Main perspective	Subject	Method

Hansen, Hegrenes, Larsen, Sehested, & Stokstad, 2005	Biological Economic	Financial impact of technical herd performance indicators	Mathematical and statistical modelling

Kristensen, Østergaard, Krogh, & Enevoldsen, 2007	Biological Economic	Financial impact of technical herd performance indicators	Mathematical modelling

Kristensen & Enevoldsen, 2008	Managerial	Farmers’ goals, beliefs attitudes and behaviour	Interviews and survey

Kristensen, Nielsen, Jensen, Vaarst, & Enevoldsen, 2008	Biological Managerial	Risk for metritis. Veterinarians perceptions and decision making	Interviews combined with quantitative analysis of herd data

Jansen, van den Borne, Renes, van Schaik, Lam, & Leeuwis, 2009	Biological Managerial	Farmers’ attitudes and behaviour	Survey

Lastein, Vaarst, & Enevoldsen, 2009	Managerial	Veterinarians’ perceptions and decision making	Field observations and interviews

Vaarst & Tind Sørensen, 2009	Biological Managerial	Dairy farmers’ perceptions and attitudes related to calf management	Semi-structured interviews

Van Asseldonk, Renes, Lam, & Hogeveen, 2010	Managerial	Farmers’ perceptions, intentions, actions and decision makings	Interviews


Parameter	Value	Parameter	Value

Radio chip	CC 2420	TsRxWait	2.2 ms

Transmit power (0 dBm)	57.42 mW	TsAck (26 bytes)	0.832 ms

Receive power	62.04 mW	TsCCA	0.128 ms

Listen power	62.04 mW	TsRxTx (TxRx turnaround)	0.192 ms

TsMaxPacket (133 bytes)	4.256 ms

Parameter	Value	Parameter	Value

Receive power	62.04 mW	TsCCA	0.128 ms

Listen power	62.04 mW	TsRxTx (TxRx turnaround)	0.192 ms

TsMaxPacket (133 bytes)	4.256 ms


	RD CsA (n = 99)	ST CsA (n = 100)

Everolimus dose (mg/day)

Month 1	1.3 ± 0.5	1.4 ± 0.6

Month 6	1.4 ± 0.6	1.3 ± 0.5

Everolimus trough concentration (ng/mL)

Month 1	5.8 ± 3.6	5.8 ± 2.5

Month 6	4.8 ± 1.7	5.3 ± 2.3

Cyclosporine dose (mg/kg/day)

Month 1	3.8 ± 1.3	4.0 ± 1.4

Month 6	2.5 ± 1.0	2.8 ± 0.8

Cyclosporine trough concentration (ng/mL)

Months 1-2	195 ± 78	209 ± 87

Month 6	120 ± 63	154 ± 68

Cyclosporine C2 concentration (ng/mL)

Months 1-2	742 ± 272	693 ± 244

Month 6	566 ± 278	707 ± 284

Steroid dosea	0.50 ± 1.40	0.32 ± 0.25

Induction therapy

Antithymocyte globulin	60 (60.6%)	61 (61.0%)

Interleukin-2 receptor antagonist	21 (21.2%)	20 (20.0%)

Everolimus dose (mg/day)

Month 1

Month 6

Everolimus trough concentration (ng/mL)

Month 1

Month 6

Cyclosporine dose (mg/kg/day)

Month 1

Month 6

Cyclosporine trough concentration (ng/mL)

Months 1-2

Month 6

Cyclosporine C2 concentration (ng/mL)

Months 1-2

Month 6

Steroid dosea

Induction therapy

Antithymocyte globulin

Interleukin-2 receptor antagonist


	Overall, n (%) n = 1096

Age in years

10–12	635 (57.9)

13–14	461 (42.1)

Pubertal age (Tanner 1–5)

Tanner 1 or 2	509 (46.4)

Tanner stage >2	584 (53.6)

Education level

Primary 5	563 (51.4)

Primary 6	533 (48.6)

Socio-economic status

Low	315 (29.0)

Medium	511 (47.1)

High	260 (23.9)

Religion

Moslem	101 (9.2)

Anglican/Pentecostal	587 (53.7)

Catholic	405 (37.1)

Family and school factors

Location of school

Rural	896 (81.8)

Urban	199 (18.2)

School absenteeism (truancy)	249 (22.7)

Ever experienced bullying at school	79 (17.3)

Number of parents alive

Both alive	905 (82.5)

None/Single parent	124 (11.3)

Access to media (TV, Social media or Tabloids)

Television	458 (41.8)

Tabloid newspapers	222 (20.3)

Social media	70 (6.4)

Ever watched pornographic content	389 (35.5)

Sexual behavior

Ever had sex	83 (7.6)


Features	Missense mutations identified as divergent variants based on the analysis of whole-genome sequence datasets from Churra and Australian Merino samples

SNP position (Oar_v3.1)	52,429,848	37,308,727	37,3557,21	37,356,400

Chromosome	2	6	6	6

dbSNP_ID	rs160159505	rs159958168	rs419074913	rs159958380

Gene	NPR2	NCAPG	LCORLa	LCORLa

Ref. (Texel Oar_v3.1) → Altb	T → C	C → T	T → A	A → T

Position in CDS	c.2540	c.1754	c.4321c	c.3642c

Base pair substitution in CDS	T → C	C → T	A → T	T → A

Breed (mutant allele)d	Merino	Merino	Churra	Merino

Codon change	cAc → cGc	TCC → TTC	ATA → TTA	GAT → GAA

Amino acid change	Histitine (H) → Arginine (R)	Serine (S)→ Phenilalanine (F)	Isoleucine (I)→ Leucine (L)	Aspartate (D) → Glutamate (E)

Protein change	NPR2_His847Arg	NCAPG_Ser585Phe	LCORL_Ile1441Leu	LCORL_Asp1214Glu

Functional impact (ensemblVEP_Oarv3.1)	Moderate	Moderate	Moderate	Moderate

Functional impact (Polyphen-2)	Benign	Benign (score = 0.252; sensitivity: 0.91; specificity: 0.88)	Benign	Benign

Functional impact (SIFT_Oarv3.1)	Tolerated	Deleterious	Tolerated (low confidence)	Tolerated

Properties of wild aminoacid	Moderate hydropathy, charge “+”	Hydrophilic, polar, no charge	Hydrophobic, no charge	Hydrophilic, charge “−”

Properties of mutant aminoacid	Hydrophilic, charge “+”	Hydrophobic, apolar, no charge	Hydrophobic, no charge	Hydrophilic,, charge “−”

Churra genotypes	TT (15)	CC (14), CT (1)	AT (1), TT (14)	AA (14), AT (1)

Australian Merino genotypes	CC (9), TC (4)	TT (9), TC (3), CC (1)	AA (9), AT (3), TT (1)	TT (9), TA (3), AA (1)


Predictors of analgesia/sedation	Univariate	Multivariate

p-value	OR (95% CI)	p-value	OR (95% CI)

Local guidelines for pain assessment	0.8953	1.10 (0.27–4.55)

NICU beds (≤ 15 beds vs >15 beds)	0.0089	3.68 (1.39–9.77)	0.0372	3.55 (1.08–11.69)

Number of NICU admission	0.0677	0.99 (0.98–1.00)


Condition	Number (%) of cases	Mean number of coded diagnoses by coding volume	Mean number of coded diagnoses by employment status	Hospital level

		Low	High	Part time	Full time	Non tertiary	Tertiary

Most complexDiabetes with complications	2007(0.5%)	7.9	7.9	7.7	7.9	7.0	9.5

Alcohol abuse	2511(0.6%)	5.3	5.4	5.6	5.3	5.1	5.9

Diabetes uncomplicated	1802(0.4%)	5.0	4.9	4.4	5.2	4.4	6.8

Depression	5860(1.4%)	4.4	4.3	4.7	4.2	4.2	4.7

Calculus of ureter	3616(0.9%)	1.5	1.7	1.5	1.7	1.6	1.4

Singleton born in hospitalLeast Complex	38,307(9.1)	1.3	1.6	1.5	1.2	1.6	1.1

Condition	Number (%) of cases	Mean number of coded diagnoses by coding volume	Mean number of coded diagnoses by employment status	Hospital level

		Low	High	Part time	Full time	Non tertiary	Tertiary

Singleton born in hospitalLeast Complex	38,307(9.1)	1.3	1.6	1.5	1.2	1.6	1.1


Sample	Accession no.	ciHHV-6	Integration sitea	Population or country

LEI-1501b	KT355575	A	19q	Leicester area (England)

HAPMAP NA18999	KY316047	A		Japan

3A-10q26.3c	KY316049	A	10q26.3 and junction isolated by PCR	Southeast England

GLA_4298d	KY316056	A		Newcastle (England)

GLA_15137e	KY316055	A		Scotland

GLA_ 25506e	KY316054	A		Scotland

7A-17p13.3c	KY316048	A	17p13.3	Southeast England

HGDP00092	KY316037	B		Balochi (Pakistan)

HGDP00813	KY316036	B		Han (China)

HGDP01065	KY316035	B	Junction isolated by PCR	Sardinia (Italy)

HGDP01077	KY316034	B	Junction isolated by PCR	Sardinia (Italy)

HAPMAP NA07022 (CEPH 1340.11)	KY316039	B		Utah Mormon (north European)

HAPMAP NA10863 (CEPH-1375.02)	KY316038	B		Utah Mormon (north European)

4B-11p15.5c	KY316044	B	11p15.5	Southeast England

BAN519f	KY316043	B		Banff (Scotland)

COR264f	KY316042	B		Cornwall (England)

CUM082f	KY316041	B		Cumbria (England)

DER512f	KY316040	B	Junction isolated by PCR	Derbyshire (England)

2B-9q34.3c	KY316045	B	9q34.3	Southeast England

1-ciHHV-6Bc	KY316046	B	Junction isolated by PCR	Southeast England

LEI-ALD	KY316033	B		Leicester area (England)

ORCA1622	KY316031	B		Orkney

ORCA1340	KY316032	B		Orkney

ORCA3835	KY316030	B		Orkney

GLA_3986d	KY316053	B		Newcastle (England)

GLA_29221e	KY316052	B		Scotland

GLA_34108e	KY316051	B		Scotland

GLA_35629e	KY316050	B		Scotland


Variable	Adjusted odds ratio	95% confidence interval

Age (years)	65-74 vs <65	1.82	1.49, 2.23

	75-84 vs <65	2.52	2.11, 3.02


Case vignette	Respondents, n	Rank sum

1	19	460.50

2	16	564.50

3	19	860.50

Case vignette	Respondents, n	Rank sum

4	19	815.50


Collaborative Problem Solving Skills	N	Mean	Standard Deviation

Social Skills	Participation	210	3.07	1.316

Perspective Taking	210	3.09	1.347

Social Regulation	210	3.10	1.364

Cognitive skills	Task Regulation	210	3.00	1.334

Knowledge Building	210	2.92	1.326


	Recall

	25 %	50 %	75 %

Precision to benign	82 %	66 %	52 %

Precision to malignant	86 %	74 %	62 %

	Precision (n=30)

Benign	85 %

Malignant	87 %

	Recall

	25 %	50 %

Precision to benign	82 %	66 %

Precision to malignant	86 %	74 %

	Precision (n=30)

Benign	85 %

Malignant	87 %


		<underline>Factor Loadings</underline>*

Items		Benefits	Barriers	Unique Variance

Osteoporosis drug treatment benefits†

1	Drug treatments can help to build strong bones	0.80	0.07	0.36

2	You would feel good about taking drug treatments to prevent osteoporosis	0.94	-0.06	0.11

3	Drug treatments can cut down the chances of broken bones	0.87	0.10	0.25

6	You would consider taking drug treatments to prevent broken bones	0.90	-0.06	0.17

11	If your doctor advised you to, you would take drug treatments to prevent broken bones	0.78	-0.12	0.36

Drug treatment barriers†

8‡	You are taking too many medications	-0.12	0.85	0.25

9‡	You have stomach problems that limit your ability to take drug treatment	0.14	0.56	0.69

		Factor Loadings*

Items		Benefits	Barriers	Unique Variance

Osteoporosis drug treatment benefits†

1	Drug treatments can help to build strong bones	0.80	0.07	0.36

2	You would feel good about taking drug treatments to prevent osteoporosis	0.94	-0.06	0.11

		Factor Loadings*

Items		Benefits	Barriers	Unique Variance

3	Drug treatments can cut down the chances of broken bones	0.87	0.10	0.25

6	You would consider taking drug treatments to prevent broken bones	0.90	-0.06	0.17

11	If your doctor advised you to, you would take drug treatments to prevent broken bones	0.78	-0.12	0.36

Drug treatment barriers†

8‡	You are taking too many medications	-0.12	0.85	0.25

9‡	You have stomach problems that limit your ability to take drug treatment	0.14	0.56	0.69


Responders	Biofeedback group	Control group

T


 	Category

Occupation	Documentation (N = 38) fraction %	Interactions (N = 36) fraction %	Adverse effects (N = 16) fraction %	Pregnancy and breastfeeding (N = 9) fraction %	Contraindications (N = 1) fraction %

Physicians (N = 54)	23/54 42.6	15/54 27.8	12/54 22.2*	3/54 5.6	1/54 1.9

Pharmacists (N = 33)	10/33 30.3	20/33 60.6**	1/33 3.0	2/33 6.1

Midwifes (N = 3)	 	 	 	3/3 100.0

Nurses (N = 2)	1/2 50.0	 	 	1/2 50.0

Other (N = 8)a	4/8 50.0	1/8 12.5	3/8 37.5

	Category

Occupation	Documentation (N = 38) fraction %	Interactions (N = 36) fraction %	Adverse effects (N = 16) fraction %	Pregnancy and breastfeeding (N = 9) fraction %	Contraindications (N = 1) fraction %

Physicians (N = 54)	23/54 42.6	15/54 27.8	12/54 22.2*	3/54 5.6	1/54 1.9

Pharmacists (N = 33)	10/33 30.3	20/33 60.6**	1/33 3.0	2/33 6.1

Midwifes (N = 3)				3/3 100.0

Nurses (N = 2)	1/2 50.0			1/2 50.0

O	4/8	1/8 12

	Category

Occupation	Documentation (N = 38) fraction %	Interactions (N = 36) fraction %	Adverse effects (N = 16) fraction %	Pregnancy and breastfeeding (N = 9) fraction %	Contraindications (N = 1) fraction %

ther (N = 8)a	 50.0	.5	3/8 37.5


	Overall frequency	Uptake of facility-based delivery

N	%	%	PRu	95 % CI	PRa	95 % CIa

Self-reported HIV status				(p < 0.001)	(p < 0.001)

Not tested / unknown status before delivery	686	(7.8)	44.4	0.56	(0.49–0.64)	0.60	(0.54–0.68)

Self-reported HIV-negative before delivery	7067	(80.3)	79.3	1.00		1.00

Self-reportedHIV-positive before pregnancy	584	(6.6)	82.2	1.04	(0.99–1.09)	1.04	(1.00–1.09)

Self-reported HIV-positive during pregnancy	459	(5.2)	80.4	1.01	(0.97–1.06)	1.05	(1.01–1.09)

	erall frequency	take of facility-based delivery

N	%	%	PRu	95 % CI	PRa	95 % CIa

Self-reported HIV status				(p < 0.001)	(p < 0.001)

Not tested / unknown status before delivery	686	(7.8)	44.4	0.56	(0.49–0.64)	0.60	(0.54–0.68)

Self-reported HIV-negative before delivery	7067	(80.3)	79.3	1.00		1.00

Self-reportedHIV-positive before pregnancy	584	(6.6)	82.2	1.04	(0.99–1.09)	1.04	(1.00–1.09)

Self-reported HIV-positive during pregnancy	459	(5.2)	80.4	1.01	(0.97–1.06)	1.05	(1.01–1.09)


	Aneurysms	Pseudo-aneurysms

Location	3% posterior	Posterior or inferior

Echocardiography

 Anatomy	Thinned myocardium	Ruptures

 Contractility	Non contractile	Dyskinesia

Consequences/Complications	Congestive heart failureEmbolic eventsVentricular arrhythmias

Therapy	Medical or Surgical therapy	Surgery

Surgical risk	Dubious	Lower than medical therapy


Impression technique	n	Internal discrepancy to master model (μm)

Premolar 34	Molar 36	FDP 34–36

Mean	(SD)	Mean	(SD)	Mean	(SD)

Conventional	10	100	6.7	127	15.7	117	11.6

Digital	10	91	8.8	95	8.5	93	8.2

Significance (2-tailed) (P < 0.01)	 	0.016	 	<0.001	 	<0.001

Impression technique	Internal discrepancy to master model (μm)

Premolar 34	Molar 36	FDP 34–36

Mean	Mean	Mean

Significance (2-tailed) (P < 0.01)	0.016	<0.001	<0.001


	Numb PTB/Pon A2B2 complex	Numb PTB/Pon B1A2 complex

FMT	41.56

Glycerol		38.18

Water	31.58	32.91

R.m.s. deviations

Bond lengths (Å)	0.010	0.011

Bond angles (°)	0.951	1.138


District	No. of IDUs	Male	Female	Married	Education	Economic status

Peshawar	100	98	2	62

Kohat	60	60	-	30	Basic: 98%	< 1$/day: 95%

Mardan	40	40	-	28	High: 2%	Well off: 5%

Total	200	198	2	120

District	No. of IDUs	Male	Female	Married

Total	200	198	2	120


Gene	Primer	Annealing Temp (° C)

Fshr	F: TGGAGGCGGCAAACCTCTGAAC	65

R: TCTGGCTTTGGCGAGCAGGTC

Oct-4A	F: CCATGTCCGCCCGCATACGA	61

R: GGGCTTTCATGTCCTGGGACTCCT

Total	F: CCTGGGCGTTCTCTTTGGAAAGGTG	68

Oct-4	R: GCCTGCACCAGGGTCTCCGA

Nanog[34]	F: CAGGAGTTTGAGGGTAGCTC	61

R: CGGTTCATCATGGTACAGTC

Stella	F: ACGCTTTGGATGATACAGACGTCC	67

R: GCGCTTTGAACTTCCCTCCGGA

Fragilis	F: GGGGTGACTGAGCTGGGGGAA	65

R: TGTCCCTAGACTTCACAGAGTAGGC

Nobox	F: AGGGTGCTGAGAGGGTGGCAG	66

R: GGCGATACTAGTGCCCCAGGAC

HoxA10	F:CACTTGTCCGGCACCCCTTCG	65

R: TTCGCCTTTGGAACTGCCTTGAC

Mvh	F: AGTGGAAGTGGTCGAGGTGGT	61

R: TGCCGGTGGTGCATCATGTCC

Scp3	F: TGTTGCAGCAGTGGGAACTGGAT	68

R: CCATCTCTTGCTGCTGAGTTTCCA

Dmc-1	F: TGGGGAATTGGCTGAACGCC	68

R: CAGGCATCTCGGGGCTGTCATAA

Stra8	F: GTTTCCTGCGTGTTCCACAAG	61

R: CACCCGAGGCTCAAGCTTC

18s	F:GGAGAGGGAGCCTGAGAAAC	61

R: CCTCCAATGGATCCTCGTTA

Gapdh[34]	F: GTCCCGTAGACAAAATGGTGA	58

 	R: TGCATTGCTGACAATCTTGAG

Gene	Primer	Annealing Temp (° C)

Fshr	F: TGGAGGCGGCAAACCTCTGAAC	65

R: TCTGGCTTTGGCGAGCAGGTC

Oct-4A	F: CCATGTCCGCCCGCATACGA	61

R: GGGCTTTCATGTCCTGGGACTCCT

Total	F: CCTGGGCGTTCTCTTTGGAAAGGTG	68

Oct-4	R: GCCTGCACCAGGGTCTCCGA

Nanog[34]	F: CAGGAGTTTGAGGGTAGCTC	61

R: CGGTTCATCATGGTACAGTC

Stella	F: ACGCTTTGGATGATACAGACGTCC	67

R: GCGCTTTGAACTTCCCTCCGGA

Fragilis	F: GGGGTGACTGAGCTGGGGGAA	65

R: TGTCCCTAGACTTCACAGAGTAGGC

Nobo	F: 	66

Gene	Primer	Annealing Temp (° C)

x	AGGGTGCTGAGAGGGTGGCAG

R: GGCGATACTAGTGCCCCAGGAC

HoxA10	F:CACTTGTCCGGCACCCCTTCG	65

R: TTCGCCTTTGGAACTGCCTTGAC

Mvh	F: AGTGGAAGTGGTCGAGGTGGT	61

R: TGCCGGTGGTGCATCATGTCC

Scp3	F: TGTTGCAGCAGTGGGAACTGGAT	68

R: CCATCTCTTGCTGCTGAGTTTCCA

Dmc-1	F: TGGGGAATTGGCTGAACGCC	68

R: CAGGCATCTCGGGGCTGTCATAA

Stra8	F: GTTTCCTGCGTGTTCCACAAG	61

R: CACCCGAGGCTCAAGCTTC

18s	F:GGAGAGGGAGCCTGAGAAAC	61

R: CCTCCAATGGATCCTCGTTA

Gapdh[34]	F: GTCCCGTAGACAAAATGGTGA	58

	R: TGCATTGCTGACAATCTTGAG


	Cohorta	Age (years)	Effect	Measurement	Reference

Verbal functions

 Vocabulary	Oswego	3	↓	MSCA Word Knowledge	Stewart et al. 2003b

		4.5	–	MSCA Word Knowledge	Stewart et al. 2003b

	Michigan	4	–	PPVT	Jacobson et al. 1990

		11	↓	WISC-R Vocabulary	Jacobson and Jacobson 1996

		11	↓	WRMT Word Comprehension	Jacobson and Jacobson 1996

	Faroe Islands	7	–b	BNT	Grandjean et al. 2001

 Verbal comprehension	Netherlands	3.5	↓c	RLDS	Patandin et al. 1999b

 Reading comprehension	Michigan	11	↓	WRMT Reading Comprehension	Jacobson and Jacobson 1996

 Verbal abstraction	Michigan	11	↓	WISC-R Similitudes	Jacobson and Jacobson 1996

	Faroe Islands	7	–	WISC-R Similitudes	Grandjean et al. 2001

Visual–spatial functions

 Visuo-motor integration	Oswego	3	↓	MSCA Block Building	Stewart et al. 2003b

		4.5	–	MSCA Block Building	Stewart et al. 2003b

	Michigan	4	–	BTVMI	Jacobson et al. 1990

	Netherlands	9	–	Rey Complex Figure Test copy	Vreugdenhil et al. 2004a

	Faroe Islands	7	–	WISC Block Design	Grandjean et al. 2001

 Mental rotation	Michigan	11	–	Mental Rotation	Jacobson and Jacobson 2003

 Visual discrimination	Michigan	4	–	KMFF	Jacobson et al. 1992


Period	Experimental Station	Control Station

Male	Female	Total	Number of trains	Male	Female	Total	Number of trains

Pre	666	575	1,241	257	290	216	506	239

Intervention	1,115	1,164	2,279	247	243	216	459	246

Post	585	555	1,140	254	254	199	453	253

Period	Experimental Station	Control Station

Male	Female	Total	Number of trains	Male	Female	Total

Pre	666	575	1,241	257	290	216	506

Intervention	1,115	1,164	2,279	247	243	216	459

Post	585	555	1,140	254	254	199	453

Control Station

Number of trains

239

246

253


Characteristics	Values

Sex

Male	41 (41.4%)

Female	58 (58.6%)

Profession

Medical Staff	31 (31.3%)

Nursing Staff	68 68.7%)

Age

Years 20 – 29	59 (59.6%)

Years 30 – 39	37 (37.4%)

Years 40 – 49	2 (2.0%)

Characteristics	Values

Nursing Staff	68 68.7%)

Age

Years 20 – 29	59 (59.6%)

Years 30 – 39	37 (37.4%)

Years 40 – 49	2 (2.0%)


Drug	Theoretical Plates (n=6)	Tailing Factor (n=6)	Capacity Factor (n=6)


Technique	Detection capability (mutant DNA/total DNA) (%)

Sanger sequencing	>10

Pyrosequencing	10

Next-generation sequencing	>1

Real-time	1

ARMS	0.1

Digital droplet PCR, BEAMing, PAP, TAM-seq, Safe-SeqS, CAPP-seq, PARE	<0.01

Technique	Detection capability (mutant DNA/total DNA) (%)

Sanger sequencing	>10

Pyrosequencing	10

Next-generation sequencing	>1

Rea	1

l-time

ARMS	0.1

Digital droplet PCR, BEAMing, PAP, TAM-seq, Safe-SeqS, CAPP-seq, PARE	<0.01


	dry season	wet season

	n	g kg−1 DM	n	g kg−1 DM

greater kudu (Tragelaphus scriptus)	14	22	±6	20	26	±16

giraffe (Giraffa camelopardalis)	13	20	±6	18	24	±11

nyala (Tragelaphus angasi)	9	46	±12	6	30	±14

impala (Aepyceros melampus)	15	99	±28	20	147	±70

waterbuck (Kobus ellipsiprymnus)	5	117	±31	19	117	±32

sable antelope (Hippotragus niger)	8	59	±6	9	52	±10

roan antelope (Hippotragus equinus)	5	128	±10	7	95	±29

blue wildebeest (Connochaetes taurinus)	15	138	±11	19	132	±18

tsessebe (Damaliscus lunatus)	3	140	±28	16	131	±23

African buffalo (Synceros caffer)	15	146	±24	20	121	±20

black rhino (Diceros bicornis)	10	17	±6	—	—

African elephant (Loxodonta africana)	20	47	±7	20	59	±14

warthog (Phacochoerus aethiopicus)	6	100	±12	6	163	±57

plains zebra (Equus burchelli)	6	126	±19	6	126	±16

white rhino (Ceratotherium simum)	10	75	±13	—	—


Data set (training number, category)	 	MHW-KELM	Gauss-KELM	Poly-KELM	Original ELM	SCG-BP

Wine Quality (2000, 7)	Mean	54.59	49.69	52.14	45.79	<10

Std.	±0.35	±0.52	±0.28	±0.85

p value	1.00	1.04e − 06	7.82e − 03	3.27e − 09	0

Time	1.159	1.133	1.372	3.520	7.159


Author, Year	Country	Study Design	Sample Size	Exposure Assessment	Outcome	Confounding Factors	Potential for Bias	Effect Size	Quality Score

Preterm birth and Birth weight

Ando and Hattori, 1973 [10]	Japan	Case-control study	713	Objective assessment, aircraft noise, ECPNL (dB)	LBW (<2500 g)	Gender, maternal age, occupation, parity	High	Higher rate of LBW in noisy area above 75 dBA	8

Knipschild et al., 1981 [11]	Netherlands	Case-control study	1840	Objective assessment, aircraft noise, 3 subgroups Ldn < 65 dBA, Ldn 65–70 dBA, Ldn > 70 dBA	LBW	Gender, parental income	High	18% LBW in low noise exposed group, 24% LBW in high noise exposed group, 29% in noise exposed above 70 dBA Dose response relationship between aircraft noise and LBW	8

Schell, 1981 [12]	USA	Cross-sectional study	115	Objective assessment, aircraft noise, SEL = 75–100 dBA	Birth weight Gestational length	Maternal age, obstetric history, parental weight and height, education, smoking, family income	High	r = −0.04, p = 0.76 males r = −0.22, p = 0.014 females r = −0.18, p = 0.16 males r = −0.38, p = 0.008 females	11

Matsui et al., 2003 [13]	Japan	Survey	160,460 births	Objective assessment, aircraft noise, WECPNL (dB) Control group <75 dBA Exposed subgroups 75–80 dBA, 81–85 dBA, >85 dBA	LBW (<2500 g) Preterm birth (<37 weeks)	Gender, maternal age, socio-economic status, live birth order No adjustment for smoking	High	OR = 1.32 (95% CI 1.18–1.48), p = 0.0001 in the highest level of exposure compared to control group OR = 1.25 (95% CI 1.1–1.4), p = 0.0018 in the highest level of exposure compared to control group	10

Congenital malformations

Jones and Tauscher, 1978 [14]	USA	Ecological study	225146 births 2105 defects	Above vs. below >90 dBA	Birth defects	Information not provided	High	1185 vs. 737 per 100,000 births p < 0.02	8

Edmonds et al., 1979 [15]	USA	Survey	1745 birth defects	Objective assessment, aircraft noise, high noise level exposure above 65 dBA Ldn	17 categories of birth defects	Socioeconomic status, race	High	Non significant differences in rates of birth defects in exposed and non-exposed groups	10

Author, Year	Country	Study Design	Sample Size	Exposure Assessment	Outcome	Confounding Factors	Potential for Bias	Effect Size	Quality Score

Preterm birth and Birth weight

Ando and Hattori, 1973 [10]	Japan	Case-control study	713	Objective assessment, aircraft noise, ECPNL (dB)	LBW (<2500 g)	Gender, maternal age, occupation, parity	High	Higher rate of LBW in noisy area above 75 dBA	8

Knipschild et al., 1981 [11]	Netherlands	Case-control study	1840	Objective assessment, aircraft noise, 3 subgroups Ldn < 65 dBA, Ldn 65–70 dBA, Ldn > 70 dBA	LBW	Gender, parental income	High	18% LBW in low noise exposed group, 24% LBW in high noise exposed group, 29% in noise exposed above 70 dBA Dose response relationship between aircraft noise and LBW	8

Schell, 1981 [12]	USA	Cross-sectional study	115	Objective assessment, aircraft noise, SEL = 75–100 dBA	Birth weight Gestational length	Maternal age, obstetric history, parental weight and height, education, smoking, family income	High	r = −0.04, p = 0.76 males r = −0.22, p = 0.014 females r = −0.18, p = 0.16 males r = −0.38, p = 0.008 females	11

Matsui	Japan		160,460 birth	Objective assessment, aircraft noise, WECPNL (dB) Control group <75 dBA Exposed subgroups 75–80 dBA, 81–85 dBA, >8	LBW (<2500 g) Preter	Gender, maternal age, socio-economic status, 	High	OR = 1.32 (95% CI 1.18–1.48), p = 0.0001 in the highest level of exposure compared to control group OR = 1.25 (95% CI 1.1–1.4), p = 0.0018 in the highest level of exposure compa	10

 et al., 2003 [13]		Survey	s	5 dBA	m birth (<37 weeks)	live birth order No adjustment for smoking		red to control group

Congenital malformations

Jones and Tauscher, 1978 [14]	USA	Ecological study	225146 births 2105 defects	Above vs. below >90 dBA	Birth defects	Information not provided	High	1185 vs. 737 per 100,000 births p < 0.02	8

Edmonds et al., 1979 [15]	USA	Survey	1745 birth defects	Objective assessment, aircraft noise, high noise level exposure above 65 dBA Ldn	17 categories of birth defects	Socioeconomic status, race	High	Non significant differences in rates of birth defects in exposed and non-exposed groups	10


Research site identifier	Site A	Site B	Site C	Site D

Telehealth deployment

Year of introduction	2007	2009	2006	2010

Equipment purchased (P) or leased (L)	P	P	L	P

No. of telehealth units available for usea	165	79	n/a	40

No. of telehealth units in useb	104	39	200	34

Referral routes into telehealth

Community matrons	✓	✓	✓	✓

Case managers	✓			✓

Specialist respiratory nurses	✓	✓	✓

Specialist heart failure nurses	✓	✓	✓

GPs	✓

Telehealth stakeholders

NHS community healthcare provider	✓		✓	✓

NHS hospital trust	✓			✓

Clinical commissioning group		✓	✓

Equipment manufacturer	✓	✓	✓	✓

Local authority	✓	✓	✓

Community interest company		✓	✓

Private company		✓	✓

Research site identifier	Site A	Site B	Site C	Site D

Telehealth deployment

Year of introduction	2007	2009	2006	2010

Equipment purchased (P) or lease	P

d (L)		P	L	P

No. of telehealth units available for usea	165	79	n/a	40

No. of telehealth units in useb	104	39	200	34

Referral routes into telehealth

Community matrons	✓	✓	✓	✓

Case managers	✓			✓

Specialist respiratory nurses	✓	✓	✓

Specialist heart failure nurses	✓	✓	✓

GPs	✓

Telehealth stakeholders

NHS community healthcare provider	✓		✓	✓

NHS hospital trust	✓			✓

Clinical commissioning group		✓	✓

Equipment manufacturer	✓	✓	✓	✓

Local authority	✓	✓	✓

Community interest company		✓	✓

Private company		✓	✓


Mutation	Gene	Mutation type	AA	References

m.3730T>Y	ND1	Point mutation	Y142H	[39,48]

m.3425T>Y	ND1	Point mutation	V40A	[39,48]

m.5212T>C	ND2	Point mutation	L248P	[39]

m.10844A>C	ND4	Point mutation	T29P	[39]

m.14510delA	ND6	Point mutation	-	[39]

Mutation	Gene	Mutation type

m.3730T>Y	ND1	Point mutation

m.3425T>Y	ND1	Point mutation

m.5212T>C	ND2	Point mutation

m.10844A>C	ND4	Point mutation

m.14510delA	ND6	Point mutation


Region ITS1	Region ITS2

Species	Controls	Species	Controls

Candida albicans	C7	Candida albicans	C7

Candida glabrata	C11SC	Cladosporium sp.	C11LF, C11SC

Cladosporium sp.	C12ERH,	Fusarium oxysporum	C3, C8, C10MD

Fungal sp.	C6	Malassezia restricta	C8, C12ERH

Fusarium oxysporum	C3, C4, C5, C8, C10MD	Penicillium crustosum	C11ERH

Malassezia globosa	C13MD	Phoma sp.	C13ERH

Malassezia restricta	C11SD, C12SC	Saccharomyces cerevisiae	C2

Penicillium crustosum	C11ERH	Uncultured eukaryote	C7

Phoma sp.	C13ERH	Uncultured fungus	C11SC

Rhodotorula mucilaginosa	C12SC	Uncultured malassezia	C11MD, C11SC, C12SC, C13LF

Uncultured fungus	C1, C10ERH, C11SC, C13LFC, C13MD	Pichia membranifaciens	C11MD

Uncultured malassezia	C11MD, C13SC

Uncultured rhodotorula	C11LF

Region ITS1	Region ITS2

Candida albicans	C7	Candida albicans	C7

Candida glabrata	C11SC	Cladosporium sp.	C11LF, C11SC

Cladosporium sp.	C12ERH,	Fusarium oxysporum	C3, C8, C10MD

Fungal sp.	C6	Malassezia restricta	C8, C12ERH

Fusarium oxysporum	C3, C4, C5, C8, C10MD	Penicillium crustosum	C11ERH

Malassezia globosa	C13MD	Phoma sp.	C13ERH

Malassezia restricta	C11SD, C12SC	Saccharomyces cerevisiae	C2

Penicillium crustosum	C11ERH	Uncultured eukaryote	C7

Phoma sp.	C13ERH	Uncultured fungus	C11SC

Rhodotorula mucilaginosa	C12SC	Uncultured malassezia	C11MD, C11SC, C12SC, C13LF

Uncultured fungus	C1, C10ERH, C11SC, C13LFC, C13MD	Pichia membranifaciens	C11MD

Uncultured malassezia	C11MD, C13SC

Uncultured rhodotorula	C11LF


	Dummy variable of Hospital C	Educational background	Research experience	Knowledge on EBN

Setting 	B=1.331 t=2.807 P= 0.005			B=-1.151 t=2.807 P=0.005

Nurse 		B=-0.995 t=-2.048 P= 0.041

Presentation 	B=0.951 t=2.318 P= 0.021		B=-2.398 t=-4.716 P= 0.000

Barriers scale	B=3.396 t=2.415 P= 0.016		B=-4.234 t=-2.429 P= 0.015

Facilitators scale	B=0.925 t=2.417 P=0.016


Pseudomonas aeruginosa strains	Bacteriocidal (+)	Bacteriostatic (−)

PAO1	+

PA103	+

PA14	 	−

Clinical strain	 	−

Pseudomonas aeruginosa strains	Bacteriocidal (+)	Bacteriostatic (−)

P	+

AO1

PA103	+

PA14		−

Clinical strain		−


Accession	Transcription factor family	Log2 fold

Up-regulated genes

AK322452	DREB3	2.5

BP893968	AP2d	2.7

AK320001	RAV2	2.7

AK319979	Pti4	3.4

AW034241	ERF2	4.3

AW651406	bZIP	2.6

AK224603	bZIP	2.8

AK326827	bZIP	3.1

EU636698	CONSTANS-like Zinc Finger	3.5

AJ784616	Stress-associated protein 6 (Zinc finger)	6.7

BG627283	BTF3-like (NAC)	2.9

AK324393	NAM-like	5

BM412776	WRKY	5.8

AK322575	WRKY3	14.5

TC239950	TCP	2.5

AK319300	TCP transcription factor 14	3

TA41176_4081	GRAS 6	3.3

AK325371	Putative transcription factor	3.4

BP879218	Putative Squamosa promoter-binding protein	3.5

Down-regulated genes

DB690655	CONSTANS-LIKE 16 Zinc Finger	3.9

DB697244	CONSTANS-LIKE 9 Zinc Finger	5.5

AW624869	CONSTANS-LIKE 10 Zinc Finger	6.8

AW622759	WRKY	3.9

AK247980	WRKY	5.2

AK247135	PIF1 (bHLH)	2.5

BI935893	putative bHLH	2.4

AK327992	MADS box	4

AK327530	PHD finger	2.2

BI925618	Bell-like homeodomain protein 2 (POX domain)	2.2

BI921917	Tubby-like F-box protein	2.6

Accession	Transcription factor family	Log2 fold

DB690655	CONSTANS-LIKE 16 Zinc Finger	3.9

DB697244	CONSTANS-LIKE 9 Zinc Finger	5.5

AW624869	CONSTANS-LIKE 10 Zinc Finger	6.8

AW622759	WRKY	3.9

AK247980	WRKY	5.2

AK247135	PIF1 (bHLH)	2.5

BI935893	putative bHLH	2.4

AK327992	MADS box	4

AK327530	PHD finger	2.2

BI925618	Bell-like homeodomain protein 2 (POX domain)	2.2

BI921917	Tubby-like F-box protein	2.6


REACH category and action	Identified priority programmes

Livestock and fisheries

Animal husbandry, fisheries, and insect farming	• Backyard poultry production in Nepal

• Household animal and horticulture production in Ghana

• Aquaculture development in Uganda

• Aquaculture development and nutrition education in Uganda

• School livestock programme in Ethiopia

• Conditional livestock transfer in Ethiopia

• Targeted cash and chicken transfer in Uganda

Crops/horticulture

Diversification and locally adapted varieties	• Home gardens in India

• Kitchen gardens in Bangladesh

• School‐based fruit production in Tanzania

• Home gardens and small livestock production in Uganda

• Home gardens and small livestock production in Bangladesh

Food processing, fortification, and storage

Food processing (excl. fortification)	• Complementary food processing programme in Ghana

Fortification (including salt iodization and fortification of complementary foods)	• Point of consumption fortification in Nepal

• Micronutrient sachets for home fortification in India

• Home‐based fortified flour production in Nepal

• Complementary food production in Ethiopia

• Mass media campaign on fortification with dried fish in Nigeria

Food consumption practices for healthy diets

Food‐based nutrition education	• School‐based feeding and nutrition education in Ethiopia

• Adolescent health and nutrition education in South Asia

• School‐based nutrition education in Ghana

• School‐based nutrition education in Uganda

• School‐based agriculture education in Ghana

Creating supportive environments to promote healthy diets in different settings	• School snack programme in Nepal

• Preschool feeding in Bangladesh

Enabling environment

Fiscal policy	• Milk transport subsidy in Nepal (livestock and fisheries)

• Decreasing transport costs in Tanzania (food consumption)

• Rice subsidy in Nigeria (food processing, fortification, and storage)

• Food tax and subsidy in Ghana (food consumption)

• Solar drier subsidy in Nepal (food processing, fortification, and storage)

Legislation, regulations/standards, protocols, and guidelines	• Food marketing association in Ghana (food consumption)

• Improved traditional wet markets in Tanzania (food consumption)

• Local market development in Nepal (food consumption)

• Quality assurance for infant complementary food (food consumption)

• Government quality certification seal (food consumption)

• Integrating nutrition into agriculture and health services in Tanzania (crops/horticulture)

Social norms: Education/sensitization, behaviour change communication, and social marketing	• Technology‐enabled behaviour change communication in Nigeria (food consumption)

• Nutrition education and media campaign in India (food consumption)

• Diet diversity media campaign in India (food consumption)

• Maternal nutrition media campaign in India (food consumption)

• Media and education campaign in Ethiopia (food consumption)

• Edutainment in Ethiopia (food consumption)

Vouchers or transfers (not defined by REACH)

	• Targeted and conditional cash transfer in India

	• Conditional cash transfer in Nigeria

	• Conditional cash and food transfers in Bangladesh

	• Food vouchers in India

	• Food vouchers in Tanzania

	• Conditional food transfer in Ethiopia

REACH category and action	Identified priority programmes

Livestock and fisheries

Animal husbandry, fisheries, and insect farming	• Backyard poultry production in Nepal

• Household animal and horticulture production in Ghana

• Aquaculture development in Uganda

• Aquaculture development and nutrition education in Uganda

• School livestock programme in Ethiopia

• Conditional livestock transfer in Ethiopia

• Targeted cash and chicken transfer in Uganda

Crops/horticulture

Diversification and locally adapted varieties	• Home gardens in India

• Kitchen gardens in Bangladesh

• School‐based fruit production in Tanzania

• Home gardens and small livestock production in Uganda

• Home gardens and small livestock production in Bangladesh

Food processing, fortification, and storage

Food processing (excl. fortification)	• Complementary food processing programme in Ghana

Fortification (including sa	• Point of consumption fortification in Nepal

• Micronutrient sachets for home fortificatio

lt iodization and fortification of complementary foods)	n in India

• Home‐based fortified flour production in Nepal

• Complementary food production in Ethiopia

• Mass media campaign on fortification with dried fish in Nigeria

Food consumption practices for healthy diets

Food‐based nutrition education	• School‐based feeding and nutrition education in Ethiopia

• Adolescent health and nutrition education in South Asia

• School‐based nutrition education in Ghana

• School‐based nutrition education in Uganda

• School‐based agriculture education in Ghana

Creating supportive environments to promote healthy diets in different settings	• School snack programme in Nepal

• Preschool feeding in Bangladesh

Enabling environment

Fiscal policy	• Milk transport subsidy in Nepal (livestock and fisheries)

• Decreasing transport costs in Tanzania (food consumption)

• Rice subsidy in Nigeria (food processing, fortification, and storage)

• Food tax and subsidy in Ghana (food consumption)

• Solar drier subsidy in Nepal (food processing, fortification, and storage)

Legislation, regulations/standards, protocols, and guidelines	• Food marketing association in Ghana (food consumption)

• Improved traditional wet markets in Tanzania (food consumption)

• Local market development in Nepal (food consumption)

• Quality assurance for infant complementary food (food consumption)

• Government quality certification seal (food consumption)

• Integrating nutrition into agriculture and health services in Tanzania (crops/horticulture)

Social norms: Education/sensitization, behaviour change communication, and social marketing	• Technology‐enabled behaviour change communication in Nigeria (food consumption)

• Nutrition education and media campaign in India (food consumption)

• Diet diversity media campaign in India (food consumption)

• Maternal nutrition media campaign in India (food consumption)

• Media and education campaign in Ethiopia (food consumption)

• Edutainment in Ethiopia (food consumption)

Vouchers or transfers (not defined by REACH)

	• Targeted and conditional cash transfer in India

	• Conditional cash transfer in Nigeria

	• Conditional cash and food transfers in Bangladesh

	• Food vouchers in India

	• Food vouchers in Tanzania

	• Conditional food transfer in Ethiopia


	Study wave	Study region (canton)

	MONICA I	MONICA II	MONICA III	Vaud*	Fribourg*	Ticino

Participants (n)	3,442	3,466	3,252	4,263	1,378	4,519


Source of variance	SS	df	Means square	F	P value	Partial eta squared (n)	Power

Within subjects

Time	38.50	2	19.25	0.32	0.73	0.005	0.10

Time × age	31.06	2	15.53	0.26	0.77	0.004	0.90

Time × group	272.87	2	136.43	2.25	0.11	0.036	0.45

Error	7387.84	122	60.56

Between subjects


	Candida albicans	Non-Candida albicans

Antifungals	Sa	DDSb	Rc	S	DDS	R

	n	%	n	%	n	%	n	%	n	%	n	%

AMB	57	98.3	—	—	1	1.7	31	100.0	—	—	—	—


	Family history of AA	Coronary heart disease	Hypertension	Cerebrovascular disease	Diabetes

AA (n = 169)	2	68	103	22	17

Non-AA (n = 156)	0	27	38	2	10

p value		0.000*	0.000*	0.000*	0.234

	Family history of AA	Coronary heart disease	Hypertension	Cerebrovascular disease

AA (n = 169)	2	68	103	22

Non-AA (n = 156)	0	27	38	2

p value		0.000*	0.000*	0.000*


Gene	Main associated phenotype	Gene product	Inheritance	Age of onset	Diagnostic clues

ADCY5	ADCY5-related chorea	Adenylate cyclase 5	AD/de novo	Infancy to childhood	Axial hypotonia and delayed milestonesDiurnal and sleep-related MD exacerbationsDystonia and myoclonus prominent in some cases

PDE10A	PDE10A-related chorea	Phosphodiesterase 10A	De novo/AD/AR	Infancy to childhood	Delayed motor-language milestones and dysarthria in recessive casesMRI: symmetrical T2-hyperintense bilateral striatal lesions in cases with heterozygous de novo mutations

FOXG1	Congenital Rett disease	Forkhead Box G1	De novo	Infancy to early childhood	Severe ID, absent language, acquired microcephalyMRI: corpus callosum aplasia/hypoplasia, delayed myelination, simplified gyration

ARX	Early infantile epileptic encephalopathy-type 1;X-linked mental retardation	Aristaless-related homeobox protein	XL	Infancy	Ohtahara/West syndrome, severe mental retardation, generalized dystonia/dyskinesias with recurrent status dystonicus

STXBP1	Early infantile epileptic encephalopathy-type 4	Syntaxin-binding protein 1	De novo	Early infancy to childhood	Onset of seizures within one year of age. Developmental delay, ID, autistic-like features, ataxia with or without dyskinesias/dystonia

SYT1	Severe motor delay and intellectual disability	Synaptotagmin-1	De novo	Infancy	Severely delayed motor development without seizures

UNC13A	Congenital encephalopathy with dyskinesias	Unc-13 homolog A	De novo	Congenital	Developmental and speech delay; ID, congenital dyskinesias with intention tremor, rare febrile seizures

GNAO1	Early infantile epileptic encephalopathy type 17/Ohtahara syndrome	Gαo subunit of GPCR	De novo	Infancy to childhood	Developmental delay and IDLong-lasting MD exacerbations not related to sleepEpilepsy can be absent or well controlled

GRIN1	Mental retardation, autosomal dominant 8	GluN1 subunit of NMDAR	De novo/AR	Infancy	Severe developmental delay and IDEarly-onset epileptic seizuresOculogyric crisesCortical blindness, dysmorphic traits, microcephaly

FRRS1L	Early infantile epileptic encephalopathy-type 37	Ferric Chelate Reductase 1-like	AR	Infancy	Psychomotor regression after normal developmentSevere encephalopathic epilepsyChoreo-athetosis in infancy/childhood, parkinsonism in adolescence

TBC1D24	Early infantile epileptic encephalopathy type 16	TBC1 domain family, member 24	AR	Infancy	Early-onset myoclonic seizuresVariable degrees of IDDystonia

GPR88	GPR88-related chorea	G protein-coupled receptor 88	AR	Infancy to childhood	Developmental and language delaySevere mental retardationScarcely progressive chorea

KMT2B	DYT28 dystonia	lysine-specific histone methyltransferase 2B	De novo/AD	Childhood-adolescence	Onset in lower limbs and prominent oro-mandibular/laryngeal involvementMild dysmorphic traits; mild IDGood and sustained response to pallidal DBS

ATP1A3	AHCRDPCAPOS syndrome	Na+/K+ ATPase, α3 subunit	De novo/AD	Infancy to fifth decade	Abrupt onset of neurological signs (dystonia, muscular weakness, ataxia)Initial hemisomatic distributionIdentifiable triggering factors

Gene	Main associated phenotype	Gene product	Inheritance	Age of onset	Diagnostic clues

STXBP1	Early infantile epileptic encephalopathy-type 4	Syntaxin-binding protein 1	De novo	Early infancy to childhood	Onset of seizures within one year of age. Developmental delay, ID, autistic-like features, ataxia with or without dyskinesias/dystonia

SYT1	Severe motor delay and intellectual disability	Synaptotagmin-1	De novo	Infancy	Severely delayed motor development without seizures

UNC13A	Congenital encephalopathy with dyskinesias	Unc-13 homolog A	De novo	Congenital	Developmental and speech delay; ID, congenital dyskinesias with intention tremor, rare febrile seizures

GNAO1	Early infantile epileptic encephalopathy type 17/Ohtahara syndrome	Gαo subunit of GPCR	De novo	Infancy to childhood	Developmental delay and IDLong-lasting MD exacerbations not related to sleepEpilepsy can be absent or well controlled

GRIN1	Mental retardation, autosomal dominant 8	GluN1 subunit of NMDAR	De novo/AR	Infancy	Severe developmental delay and IDEarly-onset epileptic seizuresOculogyric crisesCortical blindness, dysmorphic traits, microcephaly

FRRS1L	Early infantile epileptic encephalopathy-type 37	Ferric Chelate Reductase 1-like	AR	Infancy	Psychomotor regression after normal developmentSevere encephalopathic epilepsyChoreo-athetosis in infancy/childhood, parkinsonism in adolescence

TBC1D24	Early infantile epileptic encephalopathy type 16	TBC1 domain family, member 24	AR	Infancy	Early-onset myoclonic seizuresVariable degrees of IDDystonia

GPR88	GPR88-related chorea	G protein-coupled receptor 88	AR	Infancy to childhood	Developmental and language delaySevere mental retardationScarcely progressive chorea

KMT2B	DYT28 dystonia	lysine-specific histone methyltransferase 2B	De novo/AD	Childhood-adolescence	Onset in lower limbs and prominent oro-mandibular/laryngeal involvementMild dysmorphic traits; mild IDGood and sustained response to pallidal DBS

ATP1A3	AHCRDPCAPOS syndrome	Na+/K+ ATPase, α3 subunit	De novo/AD	Infancy to fifth decade	Abrupt onset of neurological signs (dystonia, muscular weakness, ataxia)Initial hemisomatic distributionIdentifiable triggering factors


	Number of events	Event rate per 100 person years (95% CI)

Any Stroke	22	4.0 (2.3–5.6)

Posterior circulation stroke	12	2.1 (0.9–3.3)

Any stroke or TIA	41	7.9 (5.5–10.4)

Posterior circulation stroke or TIA	26	4.8 (3.0–6.7)

	umber of events	100 person years (95% CI)

Any Stroke	22	4.0 (2.3–5.6)

Posterior circulation stroke	12	2.1 (0.9–3.3)

Any stroke or TIA	41	7.9 (5.5–10.4)

Posterior circulation stroke or TIA	26	4.8 (3.0–6.7)


 	Parasite density based on assumed WBC count	Parasite density based on measured WBC count	P value*

P. falciparum (n = 143)	15,208 (9,320-19,470)	13,213 (7,680-16,273)	0.49

P. vivax (n = 33)	5,364 (644-10,109)	3,538 (595-12,698)	0.96

	Parasite density based on assumed WBC count	Parasite density based on measured WBC count	P value*

P.	15,208 (9,	13,213 (7,680-16,	0


	AUCg1	AUCg2	AvgAUCg	Height cm	Weight kg	WC cm	BMI kg/m2	vWSR	TR years	Age years	LI

LI											1


Premature Ejaculation Profile Questions	Tramadol	Paroxetine	Placebo

Satisfaction with sexual intercourse (Z)	−5.31	−3.55	−1.10

p-value	0.0001	0.0001	0.270

Control over ejaculation (Z)	−5.39	−2.22	−0.09

p-value	0.0001	0.026	0.923

Ejaculation-related interpersonal difficulty (Z)	−4.001	−2.34	−1.90

p-value	0.0001	0.019	0.057

Ejaculation-related distress (Z)	−3.97	−2.29	−0.81

p-value	0.0001	0.022	0.417

Premature Ejaculation Profile Questions	Tramadol	Paroxetine

Satisfaction with sexual intercourse (Z)	−5.31	−3.55

p-value	0.0001	0.0001

Control over ejaculation (Z)	−5.39	−2.22

p-value	0.0001	0.026

Ejaculation-related interpersonal difficulty (Z)	−4.001	−2.34

p-value	0.0001	0.019

Ejaculation-related distress (Z)	−3.97	−2.29

p-value	0.0001	0.022


Algorithms	Sensitivity %, (95% CI)	Specificity %, (95% CI)	PPV %, (95% CI)	LR+ (95% CI)


Age Group

20 to 30 years old

31 to 40 years old

41 to 50 years old

51 to 60 years old

61 to 70 years old

71 to 80 years old

≥81 years old

TOTAL


Variables	Patients with RVSD (N = 32)	Patients without RVSD (N = 13)	p-value

Right atrial end-systolic area, cm2	19.7 ± 7.6	15.8 ± 8.1	0.149

Right atrial length, mm	42.9 ± 10.2	42.5 ± 11.1	0.916

Right ventricular basal diameter, mm	49.6 ± 9.3	47.7 ± 10.7	0.583

TAPSE, mm	13.1 ± 2.6	20.3 ± 2.2	<0.001*

Right ventricular S’, cm/s	10.6 ± 3.2	15.3 ± 3.9	<0.001*

RIMP	1.09 ± 0.60	1.76 ± 1.30	0.032*

RV wall thickness, mm	3.6 ± 1.2	3.5 ± 0.8	0.952

Tricuspid Valve E:A ratio	1.21 ± 0.44	0.90 ± 0.35	0.019*

Tricuspid Valve E/e’	5.08 ± 2.73	3.46 ± 1.45	0.023*

Left atrial diameter, mm	43.2 ± 6.4	41.9 ± 6.2	0.548

LV end-diastolic diameter, mm	62.0 ± 7.5	62.4 ± 11.7	0.910

LV ejection fraction, %	32.4 ± 9.3	36.6 ± 7.7	0.127

LV stroke volume index, L/m2	39.9 ± 12.3	51.4 ± 17.9	0.017

Anti-log10 mitral valve E:A	1.50 ± 0.62	1.31 ± 0.25	0.154

Mitral valve E/e’	15.96 ± 7.13	15.61 ± 7.06	0.882

PA acceleration time, ms	61.8 ± 22.4	78.9 ± 28.0	0.037*

PA systolic pressure, mmHg	47.4 ± 19.4	39.2 ± 21.5	0.246

Mean PAP, mmHg	30.6 ± 11.6	25.9 ± 13.1	0.273

Pulmonary hypertension	23 (71.9 %)	7 (53.9 %)	0.304

Variables

Right atrial end-systolic area, cm2

Right atrial length, mm

Right ventricular basal diameter, mm

TAPSE, mm

Right ventricular S’, cm/s

RIMP

RV wall thickness, mm

Tricuspid Valve E:A ratio

Tricuspid Valve E/e’

Left atrial diameter, mm

LV end-diastolic diameter, mm

LV ejection fraction, %

LV stroke volume index, L/m2

Anti-log10 mitral valve E:A

Mitral valve E/e’

PA acceleration time, ms

PA systolic pressure, mmHg

Mean PAP, mmHg

Pulmonary hypertension


Segments	Primers	Position	Length, bp

Internal standard

 P1	5′-aacatacccatggccaacct-3′	3304–3836	533

 P2	5′-ggcaggagtaatcagaggtg-3′

First cycle

 P3	5′-tgaacctacgagtacaccga-3′	7901–14220	1342

 P4	5′-ttagtagtagttactggttg-3′

Second cycle

 P5	5′-ttcatgcccatcgtcctaga-3′	8201–13851	673

 P6	5′-gttgaggtctagggctgtta-3′

Third cycle

 P7	5′-cccctctagagcccactgtaaagc-3′	8282–13650	391

 P8	5′-ggggaagcgaggttgacctg-3′

Segments	Primers	Position	Length, bp

P3	5′-tgaacctacgagtacaccga-3′	7901–14220	1342

P4	5′-ttagtagtagttactggttg-3′

Second cycle

P5	5′-ttcatgcccatcgtcctaga-3′	8201–13851	673

P6	5′-gttgaggtctagggctgtta-3′

Third cycle

P7	5′-cccctctagagcccactgtaaagc-3′	8282–13650	391

P8	5′-ggggaagcgaggttgacctg-3′


Canonical Pathways	Number of differentially expressed molecules (P-value)

	SPF	C	EF

Ranked according to ratio (differentially expressed genes/total number of genes)

Antigen Presentation Pathway	5/39 (< 0.0001)	5/39 (< 0.0001)	10/39 (< 0.0001)

Interferon Signaling	1/29 (0.1)	1/29 (0.1)	9/29 (< 0.0001)

IL-10 Signaling	1/70 (0.2)	2/70 (< 0.05)	12/70 (< 0.0001)

p38 MAPK Signaling	1/95 (0.3)	2/95 (0.1)	13/95 (< 0.001)

Cell Cycle: G2/M DNA Damage Checkpoint Regulation	N/A	N/A	7/42 (< 0.01)

Inositol Metabolism	N/A	N/A	4/24 (< 0.005)

Keratan Sulfate Biosynthesis	N/A	N/A	5/31 (< 0.05)

IL-6 Signaling	N/A	1/93 (0.41)	13/93 (< 0.0005)

Fatty Acid Metabolism	1/187 (0.5)	4/187 (< 0.05)	28/187 (< 0.0001)

Ranked according to P-value (as determined by IPA)

Total number of significant pathways	2	6	15

Fatty Acid Metabolism	1/187 (0.3)	2/187 (0.1)	28/187 (< 0.0001)

LPS/IL-1 Mediated Inhibition of RXR Function	1/170 (0.4)	2/170 (0.2)	33/170 (< 0.0001)

Tryptophan Metabolism	2/237 (0.05)	1/237 (0.4)	26/237 (< 0.0001)

β-alanine Metabolism	N/A	N/A	10/99 (< 0.0001)

Valine, Leucine and Isoleucine Degradation	N/A	N/A	12/107 (< 0.0001)


Variables	aAdjusted HR	95% CI	P value

Age (years)	1.033	1.027–1.039	< 0.001

Female sex	0.700	0.593–0.827	< 0.001

Hypertension	1.025	0.897–1.172	0.713

Diabetes mellitus	1.427	1.216–1.675	< 0.001

Preoperative severe anemia(Hb < 8.0 g/dL)	1.282	1.036–1.586	0.022

Preoperative creatinine (mg/dL)	2.022	1.711–2.389	< 0.001

Postoperative creatinine (mg/dL)	1.010	1.004–1.017	0.003

Intraoperative use of normal saline	1.030	0.905–1.172	0.656

Postoperative hyponatremia	1.331	1.148–1.542	< 0.001

Variables	aAdjusted HR	95% CI

Age (years)	1.033	1.027–1.039

Female sex	0.700	0.593–0.827

Hypertension	1.025	0.897–1.172

Diabetes mellitus	1.427	1.216–1.675

Preoperative severe anemia(Hb < 8.0 g/dL)	1.282	1.036–1.586

Preoperative creatinine (mg/dL)	2.022	1.711–2.389

Postoperative creatinine (mg/dL)	1.010	1.004–1.017

Intraoperative use of normal saline	1.030	0.905–1.172

Postoperative hyponatremia	1.331	1.148–1.542


Variables	Explanation

Measures of needs

Age-adjusted mortality

Physician density	The number of physicians who work for any medical facilities per 1,000 population

Hospital physician density	The number of physicians who work for hospitals per 1,000 population

Clinic physician density	The number of physicians who work for clinics per 1,000 population

Measures of residential quality

Urban/rural status	The metropolitan area code defined by the Ministry of Internal Affairs and Communications

1) urban centres, 2) suburban areas,

3) rural areas

Per capita income

Percent of the population	As a proxy for educational level in the community

with a university-level education

Unemployment rate	The number of unemployed individuals per the number of all individuals currently in the labour force (workforce)

Percent of white-collar workers	The number of professionals, technical workers, managers, and administrators per number of workforce

Primary school students per number	As a proxy for children’s educational opportunities

of primary schools

Crime rate	The number of crimes per total population as a proxy for neighbourhood safety

Temperature	As a proxy for climate discomfort. The discomfort index was calculated by using temperature and humidity and used in the model.

Humidity

Other factors

Total population

Hospital beds per 1,000 population

The presence or absence of	As a proxy for continuing education

medical schools


Var	Cyt	Frequency (%) of callus induction	Frequency (%) of bud induction	Average number of buds per explant

Photoperiod	Dark	Photoperiod	Dark	Photoperiod	Dark

ER	TDZ	0.00 ± 0.00 b	0.00 ± 0.00 b	0.00 ± .00 e	06.40 ± 2.97 e	0.00 ± .00 f	0.80 ± 0.29 ef


	Cut off point	Sensitivity	Specificity	PPV	NPV

Morphology(%)	5.5	66%	94%	96%	31%

Motility(%)	72.5	29%	94%	94%	26%

Concentration(million/ml)	35.5	46%	94%	96%	32%

	Cut off point	Sensitivity	Specificity	PPV	NPV

Morphology(%)	5.5	66%	94%	96%	31%

Motility(%)	72.5	29%	94%	94%	26%

Concentration(million/ml)	35.5	4	9	96	32


	Penciclovir cream (P)	Acyclovir cream (A)	Ratio (P/A)	Statistics

μg/cm2	Mean	s.e.m	Mean	s.e.m		P value

Strip 1	0.55	0.16	0.88	0.3	0.6	0.42

Strip 2	0.29	0.06	0.06	0.03	4.9	0.002

Pooled Strips	0.32	0.12	0.07	0.04	4.5	0.07

Epidermis	1.15	0.35	1.01	0.04	1.1	0.32

Dermis (residual stripped skin)	0.10	0.04	0.07	0.04	1.4	0.63

Permeation through the skin (receptor phase)	0.41	0.19	0.12	0.10	3.4	0.18

	Penciclovir cream (P)	Acyclovir cream (A)	Ratio(P/A)	Statistics

% applied dose	Mean	s.e.m	Mean	s.e.m		P value

Strip 1	1.15	0.41	0.30	0.11	3.8	0.06

Strip 2	0.61	0.16	0.02	0.01	29.1	0.002

Pooled Strips	0.67	0.31	0.02	0.01	32.3	0.04

Epidermis	2.4	0.9	0.3	0.1	7.0	0.3

Dermis (residual stripped skin)	0.17	0.07	0.02	0.01	9.1	0.06

Permeation through the skin (receptor phase)	0.68	0.33	0.04	0.03	16.7	0.06

	Penciclovir cream (P)	Acyclovir cream (A)	Ratio (P/A)	Statistics

Pooled Strips	0.67	0.31	0.02	0.01	32.3	0.04

Epidermis	2.4	0.9	0.3	0.1	7.0	0.3

Dermis (residual stripped skin)	0.17	0.07	0.02	0.01	9.1	0.06

Permeation through the skin (receptor phase)	0.68	0.33	0.04	0.03	16.7	0.06


		<underline>Percentage (%)</underline> (n = 100)	<underline>95% CI</underline>

Most frequent diagnostic categories *

	Neoplasm and chemotherapy	15	9 – 24

	Respiratory infections	9	4 – 16

	Asthma	5	2 – 11

	Gastroenteritis	5	2 – 11

	Appendicitis	4	1 – 10

	Epilepsy or seizure	3	0.6 – 9

	Malfunctioning device or graft	3	0.6 – 9

Length of stay

	1 day	10	5 – 18

	2 days	25	17 – 35

	3 days	24	16 – 34

	4–7 days	27	17 – 37

	8 to 103 days	14	8 – 22

Devices *

	Gastrostomy or jejuenostomy tubes	10	5 – 18

	Central venous line	7	3 – 14

	Medication nebulizer	7	3 – 14

	Ventriculoperitoneal shunt	2	0.2 – 7

	Tracheotomy	1	0.03 – 5

Number of medications §

	0	18	11 – 27

	1	20	13 – 29

	2	26	18 – 36

	3	16	10 – 26

	4	7	3 – 14

	5 or more	12	6 – 20

Number of daily medication administrations noted ‡

	0 or PRN	33	24 – 44

	1–4	30	21 – 40

	5–9	24	16 – 34

	10–22	12	6 – 20

Home nursing care	8	4 – 15

Other forms of home care	7	3 – 14

Disposition

	Home	91	84 – 96

	Transfer	3	0.6 – 9

	Death	1	0.03 – 6

	Unknown	5	2 – 11

		Percentage (%) (n = 100)	95% CI

Most frequent diagnostic categories *

	Neoplasm and chemotherapy	15	9 – 24

	Respiratory infections	9	4 – 16

	Asthma	5	2 – 11

	Gastroenteritis	5	2 – 11

	Appendicitis	4	1 – 10

	Epilepsy or seizure	3	0.6 – 9

	Malfunctioning device or graft	3	0.6 – 9

Length of stay

	1 day	10	5 – 18

	2 days	25	17 – 35

	3 days	24	16 – 34

	4–7 days	27	17 – 37

	8 to 103 days	14	8 – 22

Devices *

	Gastrostomy or jejuenostomy tubes	10	5 – 18

	Central venous line	7	3 – 14

	Medication nebulizer	7	3 – 14

	Ventriculoperitoneal shunt	2	0.2 – 7

	Tracheotomy	1	0.03 – 5

Number of medications §

	0	18	11 – 27

	1	20	13 – 29

	2	26	18 – 36

	3	16	10 – 26

	4	7	3 – 14

	5 or more	12	6 – 20

Number of daily medication administrations noted ‡

	0 or PRN	33	24 – 44

	1–4	30	21 – 40

	5–9	24	16 – 34

	10–22	12	6 – 20

Home nursing care	8	4 – 15

Other forms of home care	7	3 – 14

Disposition

		9	84

	Percentage (%) (n = 100)	95% CI

Home	1	 – 96

Transfer	3	0.6 – 9

Death	1	0.03 – 6

Unknown	5	2 – 11


Income group	Mean reduction in daily calorie intake (kcal/person/day)

Female	Male	Overall

Income group 1 (lowest)	2.2	1.6	1.9

Income group 2	1.9	1.9	1.9

Income group 3 (highest)	1.9	2.6	2.3


Trial	Number	Setting	Trial duration	ICU	Population	Intervention	Comparator	Outcomes

Inclusion criteria	Exclusion criteria

Youness et al. [20]	33	Single-centre US	24 months	Mixed	Intubated mechanically ventilated patients with new-onset (<48 h) atelectasis	CF, uncontrolled asthma, COPD, pneumothorax, pleura effusion, tumor-associated atelectasis, severe hypoxemia, hemodynamic instability, allergy to dornase alfa, use of nebulized acetylcysteine and pregnancy	Nebulized dornase alfa 2.5 mg twice daily in 7 days or until resolution of atelectasis	(1) Placebo (isotonic saline) same volume, dosage, and duration of treatment	Mortality

(2) Hypertonic saline (same volume, dosage, and duration of treatment)

Zitter et al. [19]	30	Single-centre US	12 months	Mixed	Mechanically ventilated patients aged >18 years with new-onset (<24 h) atelectasis	Quadriplegia, chronic ventilator dependence, pneumothorax, frank hemoptysis, elevated intracranial pressure, pregnancy or active nursing, concurrent use of other investigational drugs, and allergy to dornase alfa, Chinese hamster ovary-derived biologics or other components of the active component	Nebulized dornase alfa 2.5 mg twice daily until extubation, death or transfer (maximum 30 days)	Placebo (isotonic saline) same volume, dosage, and duration of treatment	Mortality

Trial	Number	Setting	Trial duration	ICU	Population	Intervention	Comparator

Inclusion criteria	Exclusion criteria

Youness et al. [20]	33	Single-centre US	24 months	Mixed	Intubated mechanically ventilated patients with new-onset (<48 h) atelectasis	CF, uncontrolled asthma, COPD, pneumothorax, pleura effusion, tumor-associated atelectasis, severe hypoxemia, hemodynamic instability, allergy to dornase alfa, use of nebulized acetylcysteine and pregnancy	Nebulized dornase alfa 2.5 mg twice daily in 7 days or until resolution of atelectasis	(1) Placebo (isotonic saline) same volume, dosage, and duration of treatment

(2) Hypertonic saline (same volume, dosage, and duration of treatment)

Zitter et al. [19]	30	Single-centre US	12 months	Mixed	Mechanically ventilated patients aged >18 years with new-onset (<24 h) atelectasis	Quadriplegia, chronic ventilator dependence, pneumothorax, frank hemoptysis, elevated intracranial pressure, pregnancy or active nursing, concurrent use of other investigational drugs, and allergy to dornase alfa, Chinese hamster ovary-derived biologics or other components of the active component	Nebulized dornase alfa 2.5 mg twice daily until extubation, death or transfer (maximum 30 days)	Placebo (isotonic saline) same volume, dosage, and duration of treatment


Cell Type	Number of Genes	% of Genes

adipocyte	188	21.23

alveolar macrophage	127	14.11

B-lymphoblast	106	12.58

B-lymphocyte	628	70.79

brown adipose	1	0.11

cardiac muscle cell	33	3.72

chondrocyte	33	3.72

dendritic cell	56	6.35

endothelium	194	21.88

eosinophil	1	0.11

epithelium	604	68.49

fibroblast	485	54.92

foam cell	25	2.74

germ cell	435	49.02

glial cell	432	48.69

glioblast	42	4.7

granulosa cell	63	7.22

hepatocyte	3	0.33

keratinocyte	287	32.17

leukocyte	295	33.26

lymphocyte	86	9.63

macrophage	194	21.88

mast cell	2	0.22

melanocyte	283	31.84

monocyte	13	1.42

muscle cell	233	26.37

myeloid cell	149	17.4

natural killer cell	339	38.84

neuroblast	396	44.86

neuroepithelium	143	16.19

neuron	124	14

pericyte	128	14.66

platelet	1	0.11

proerythroblast	65	7.77

promyeloblast	14	1.86

promyelocyte	44	5.03

retinal pigment epithelium	514	57.55

skeletal muscle cell	499	56.56

smooth muscle cell	128	14.77

squamous cell	376	42.67

stem cell	626	70.79

T-lymphocyte	359	40.92

transitional	194	22.21

white adipose	41	4.81

Cell Type	Number of Genes	% of Genes

adipocyte	188	21.23

alveolar macrophage	127	14.11

B-lymphoblast	106	12.58

B-lymphocyte	628	70.79

br	1	0.1

own adipose		1

cardiac muscle cell	33	3.72

chondrocyte	33	3.72

dendritic cell	56	6.35

endothelium	194	21.88

eosinophil	1	0.11

epithelium	604	68.49

fibroblast	485	54.92

foam cell	25	2.74

germ cell	435	49.02

glial cell	432	48.69

glioblast	42	4.7

granulosa cell	63	7.22

hepatocyte	3	0.33

keratinocyte	287	32.17

leukocyte	295	33.26

lymphocyte	86	9.63

macrophage	194	21.88

mast cell	2	0.22

melanocyte	283	31.84

monocyte	13	1.42

muscle cell	233	26.37

myeloid cell	149	17.4

natural killer cell	339	38.84

neuroblast	396	44.86

neuroepithelium	143	16.19

neuron	124	14

pericyte	128	14.66

platelet	1	0.11

proerythroblast	65	7.77

promyeloblast	14	1.86

promyelocyte	44	5.03

retinal pigment epithelium	514	57.55

skeletal muscle cell	499	56.56

smooth muscle cell	128	14.77

squamous cell	376	42.67

stem cell	626	70.79

T-lymphocyte	359	40.92

transitional	194	22.21

white adipose	41	4.81


Demographic data	Control group N = 30	Endometriosis group N = 30	Ectopic group N = 22	P value (control v endometriosis)

Age, median (range)	40 (25–47)	36 (18–45)	40 (24–51)	P = 0.056

BMI, median (range)	27 (20–42)	26 (20–38)	27.1 (18–32)	P = 0.37

Parity, median (range)	2 (1–4)	1 (0–3)	1 (0–2)	P < 0.0001

Smoker	9/30 (30%)	5/30 (17%)	1/22 (5%)	P = 0.36

Endometriosis stage, median (range)	–	2 (1–4)	4 (1–4)	N/A


Challenge	CE	Matched compound	MF	RMF	Prob

1	10 eV	Kanamycin A	645	879	98.88

20 eV	Kanamycin A	501	833	98.81

30 eV	Kanamycin A	531	776	98.66


Motif	Count	Average length (bp)	Count/Mbp

Mononucleotide	19	15.89	9.35

Dinucleotide	30	29.60	14.76

Trinucleotide	92	19.99	45.26

Tetranucleotide	39	15.87	19.19

Pentanucleotide	27	16.96	13.28

Hexanucleotide	9	20.22	4.43

Total	216	19.85	106.27

Motif	Count	Average length (bp)

Mononucleotide	19	15.89

Dinucleotide	30	29.60

Trinucleotide	92	19.99

Tetranucleotide	39	15.87

Pentanucleotide	27	16.96

Hexanucleotide	9	20.22

Total	216	19.85


Characteristic

	 n = 1,729

Age (y)	Median (IQR)	69 (62-74)

	Range	22-93

Male sex, n (%)	1,156 (66.9)

Absence of previous iodinated contrast media injections, n (%)	973 (56.3)

History of adverse reaction to iodinated contrast media, n (%)	45 (2.6)

History of allergy, n (%)	164 (9.5)

History of asthma, n (%)	23 (1.3)

Use of corticosteroid at entry, n (%)	28 (1.6)

Child–Pugh classification, n (%)

 A	1427 (82.5)

 B or C	302 (17.5)

Renal function at entry

eGFR (ml/min), Median (IQR)	 73.6 (61.7-87.3)

Presence of renal impairment, n (%)	383 (22.2)


Compounds	Content (Mean ± SD, n = 3)

mg/g

Paeoniflorin	59.55 ± 0.39

Glycyrrhizin	12.13 ± 0.01

Compounds	Content (Mean ± SD, n = 3)

mg/g

Glycyrrhizin	12.13 ± 0.01


Guarantee the follow-up and referral to medical services of individuals with a positive diagnosis

PROCESS MEASURE	Indicator description	Method of Data collection	Data Collection Frequency

Monitoring of the number of individuals infected with HIV that have received medical care	Number of individuals infected with HIV that have received medical care/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year	NGO	12 months

Monitoring of the number of individuals infected with HIV that are referred to other health services	Number of individuals infected with HIV that are referred to other health services/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year	NGO	12 months

Monitoring of the number of individuals referred to each service	Numbers of individuals referred to each service	NGO	12 months

Monitoring of the number of people working in a service	Number of people working in a service	NGO	12 months

Monitoring of the hours dedicated to each activity	Hours dedicated to each activity	NGO	12 months

OUTCOME MEASURE	Indicator description	Method of Data collection	Data Collection Frequency

Level of satisfaction with the service	Number of individuals infected with HIV that have received care, have responded to the satisfaction questionnaire, and have a high level of satisfaction/Number of infected individuals that have received care and have responded to the questionnaire	NGOAnswers to the satisfaction questionnaire	12 months

Monitoring of the questionnaire of quality of life answers of individuals attended by the NGO	Descriptive analysis and monitoring of the global score and score by dimensions of the questionnaire of quality of life answers of individuals infected with HIV and attended by the NGO	NGOAnswers to the QQV	12 months

Guarantee the follow-up and referral to medical services of individuals with a positive diagnosis

PROCESS MEASURE	Indicator description

Monitoring of the number of individuals infected with HIV that have received medical care	Number of individuals infected with HIV that have received medical care/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year

Monitoring of the number of individuals infected with HIV that are referred to other health services	Number of individuals infected with HIV that are referred to other health services/Number of individuals infected with HIV attended and that have received health care by the NGO in the evaluation year

Monitoring of the number of individuals referred to each service	Numbers of individuals referred to each service

Monitoring of the number of people working in a service	Number of people working in a service

Monitoring of the hours dedicated to each activity	Hours dedicated to each activity

OUTCOME MEASURE	Indicator description

Level of satisfaction with the service	Number of individuals infected with HIV that have received care, have responded to the satisfaction questionnaire, and have a high level of satisfaction/Number of infected individuals that have received care and have responded to the questionnaire

Monitoring of the questionnaire of quality of life answers of individuals attended by the NGO	Descriptive analysis and monitoring of the global score and score by dimensions of the questionnaire of quality of life answers of individuals infected with HIV and attended by the NGO

Guarantee the follow-up and referral to medical services of individuals with a positive diagnosis

Method of Data collection	Data Collection Frequency

NGO	12 months

NGO	12 months

NGO	12 months

NGO	12 months

NGO	12 months

Method of Data collection	Data Collection Frequency

NGOAnswers to the satisfaction questionnaire	12 months

NGOAnswers to the QQV	12 months